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The recognition and treatment of pain is a constant challenge in the care of newborn
infants. Various behavioural and physiological measures exist, but mainly for acute
pain. They are also less applicable in the sickest and most premature infants. Most
existing neurochemical measures are markers for stress rather than pain. Both
substance P (SP) and neurokinin A (NKA) have been postulated to be involved in
persistent pain in adult studies, but never previously researched in newborn infants.
Methods of sample handling and analysis were developed to accommodate neonatal
microsamples. Sample extraction was found to be essential, as were the speed of
sample collection and the use of polypropylene materials during sample handling.
The clinical study enrolled 174 infants of different gestational ages, who had serial
measurements of SP, NKA and Cortisol performed in plasma and saliva samples.
Plasma SP concentrations in neonates ranged from 0.0-11.2 pmol/L (median 1.7
pmol/L) and NKA concentrations from 1.8-74.6 pmol/L (median 6.0 pmol/L).
Gestation and birth weight had no significant correlation with peptide concentrations.
Postnatally, there was a gradual rise in median plasma SP and NKA during the first
three days which decreased again by days 7 to 14. Perinatal factors such as labour,
the mode of delivery, and epidural analgesia affected NKA but not SP concentrations.
With regard to either pain or assisted ventilation, plasma SP concentrations did not
appear to be a useful marker of persistent pain or distress. Conversely, plasma NKA
concentrations showed significant changes with ventilation, which were further
modulated by the use of analgesia. Cortisol responses in the same group of infants
demonstrated significant changes with ventilation, but not with the administration of
analgesia. This suggests that although Cortisol is a useful indicator of overall stress,
NKA might be more specific for pain.
There was a weak correlation between plasma SP and NKA. Plasma SP did not
correlate with plasma Cortisol or other physiological measures of pain used in this
study. Plasma NKA did not correlate with plasma Cortisol, but showed some
correlation with behavioural pain scores. Neither neuropeptide correlated with heart
rate variability, whereas plasma Cortisol did. As with plasma Cortisol, heart rate
variability was not modulated by the use of analgesia, suggesting that both were
markers for stress but not necessarily for pain.
Worldwide, this is the first study of SP and NKA in newborn infants. Assessing pain
in neonates is a challenge, yet pain in neonates has detrimental consequences and
needs to be treated appropriately. The ability to neurochemically measure pain in
infants undergoing neonatal intensive care, as well as monitor responses to analgesia,
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Chapter 1: General introduction
1. GENERAL INTRODUCTION
1.1 The nature of pain/What is pain?
"Pain is perfect misery, the worst of evils, and, excessive, overturns all patience."
Milton. Paradise Lost.
Pain has been defined by the International Association for the Study of Pain (IASP)
(www.iasp-pain.org) as "an unpleasant sensory and emotional experience associated
with actual or potential tissue damage or described in terms of such damage... Pain
is always subjective. Each individual learns the application of the word through
experiences related to injury in early life"1. In contrast, the noxious perception of
pain without taking into account its emotional aspect is referred to as nociception.
Pain experience, therefore, involves psychological and emotional variables, and can
markedly differ between individuals, depending on previous pain experience,
biological variation, psychological aspects, and even cultural factors. There can be a
lack of correspondence between the extent of injury and the intensity of pain
experience. One difficulty with the definition of pain lies with the statement that pain
requires learning and previous experience. This would render it impossible for a fetus
or newborn to experience pain. Yet there is much evidence to prove that suffering
pain does not require previous experience (See Section 1.2). Another problem with
this definition is that infants have a limited ability to communicate pain. Fortunately,
the IASP has more recently noted that "the inability to communicate verbally does
1
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not negate the possibility that an individual is experiencing pain and is in need of
appropriate pain-relieving treatment."2
Other definitions of pain-related terms include:
Acute pain: Pain associated with a brief episode of tissue injury or inflammation
Chronic pain: Constant pain over a period of three months or longer
Hyperalgesia: An increased response to a stimulus which is normally painful
Allodynia: Pain due to a stimulus which does not normally provoke pain
Neurogenic pain: Pain initiated or caused by a primary lesion, dysfunction, or
transitory perturbation in the peripheral or central nervous system
1.1.1 The function ofpain
The pain experience serves to inform the sufferer of potential or existing tissue injury.
Patients who lack pain sensation are vulnerable to more extensive trauma, as they are
deficient in a self-protective mechanism. As such, pain in an individual can also
serve to warn others about a potential threat to safety.
1.1.2 Pain fibres
Sensory nerve terminals that are activated during a painful stimulus include low
threshold Ap mechanoreceptors, and nociceptive A5 and C fibres. A5 fibres are
thinly myelinated high threshold mechanoreceptors, while C fibres are unmyelinated
polymodal nociceptors. Nociceptors are triggered by a variety of noxious stimuli,
including low extracellular pH, heat, and capsaicin (which is derived from hot chilli
peppers). C fibres are divided into two groups: those that contain neuropeptides (e.g.
2
Chapter 1: General introduction
substance P or SP) and express the neurotrophin receptor for nerve growth factor,
and those which bind isolectin B4 (IB4) and express receptors for the neurotrophin
glial cell-derived neurotrophic factor (GDNF). C fibres terminate in the Rexed's
lamina II of the substantia gelatinosa of the dorsal horn. This is a site pain research
has focused on, rich in neuropeptide and enzyme activity, and thought to be an area
ofmodulation3.
In adults, lamina II of the substantia gelatinosa of the dorsal horn is exclusively
occupied by C fibres, but in neonatal rat pups, it is also occupied by transient A fibre
terminals. These may be pressure-sensitive receptors, and there is some evidence that
rapid nociceptive responses are mediated via these fibres in the newborn4.
1.1.3 Pain pathways
A diagrammatic representation of the neuronal pathways involved in pain signal
transmission and modulation is shown in Figure 1.1.
3
Figure 1.1: Pain pathways
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1.1.4 Nociceptor differentiation
Nociceptors are specified early in development, even before they form contacts with
their future innervation targets4. In the dorsal root ganglia, the large-diameter A
fibres are born before the small-diameter C ones. The small-diameter fibres express
tyrosine kinase receptor A (TrkA) and appear to be under separate transcriptional
control to the large-diameter fibres, which express tyrosine kinase receptors B and C.
Around the time of birth in rat pups, a subpopulation of nociceptors downregulates
the expression of TrkA and becomes the IB4-positive nociceptors. The rest continue
to differentiate depending on neurotrophin levels during the postnatal period, and
also peripheral target innervation. Subsequently, the innervation density of
nociceptors in the skin is regulated by local neurotrophins, and can be upregulated by
neonatal skin wounding which increases local neurotrophin levels, resulting in
hyperinnervation of the skin5.
4
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Centrally, lamina I projection neurones are complete before the generation of local
circuit modulatory neurones, indicating that nociceptive transmission from the spinal
cord to higher centres could develop before local modulation is ready4. At premature
birth, a noxious stimulus peripherally results in a whole-body untuned movement
response, which only becomes a more specific limb withdrawal with ongoing
development. Cutaneous reflexes have lower thresholds and result in a more
prolonged muscle contraction response in prematurity. Local modulation
subsequently occurs via GABA-mediation initially, and via glycinergic synapses
later on in postnatal life. Central modulation via descending fibres which contain
serotonin also takes place even later as there is prolonged postnatal maturation of the
descending pathways.
1.2 Evidence for pain in neonates
Pain in infants was largely ignored till the late 1960s. This was due to a combination
of misconceptions within the medical and nursing professions: firstly, that infants
had a low perception of pain; secondly, that they would be highly susceptible to
adverse reactions from analgesia and anaesthesia; and thirdly, that there was no need
to treat their pain as they would have no memory of it. For example, infants would
undergo a thoracotomy for patent ductus arteriosus ligation using only nitrous oxide
and tubocurarine.
How then do we know that human neonates feel pain?
5
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1.2.1 Anatomical evidence
The neuroanatomical requirements for pain perception are present even in the most
preterm infants. Figure 1.2 summarises the fetal development of various components
of the nervous system.
Figure 1.2: Development of some aspects of the fetal hypothalamic-pituitary axis,
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From Glover V and Giannakoulopoulos X. Stress and Pain in the Fetus. Baillieres
Clinical Paediatrics, 1995.
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1.2.1.1 Neuronal distribution
In the human embryo, both A and C dorsal root ganglion cells are formed by 5 weeks
of development. The sensory neurones that give rise to nociceptors grow out from
the dorsal root ganglion during embryo development, and proceed to innervate the
skin in an organised proximodistal manner6. Large Ap fibres develop by 8 weeks7,
while C fibres develop later. Innervation of the perioral area occurs by 7 weeks, the
face and hands by 11 weeks, trunk and legs by 15 weeks. By 20 weeks in humans,
these neurones reach the most distal skin of the foot . The cortex has its full
complement of 109 neurones by 20 weeks' gestation, and corticothalamic connections
are complete by 24 weeks' gestation. Further growth of synaptic and dendritic
formations then continues to occur during fetal and postnatal development.
1.2.1.2 Neuropeptide distribution
Pain-related neurotransmitters or neuromodulators in the spinal cord, including SP,
enkephalin, somatostatin, calcitonin gene-related peptide (CGRP), vasoactive
intestinal peptide (VIP), and other ligands, seem to follow similar developmental
patterns of expression in newborn rats and human neonates (Figure 1.3)9.
Neurotransmitters act via synaptic receptors to produce a functional response, whilst
neuromodulators modify the state of the receptor or second messenger to facilitate or
reduce the action of a neurotransmitter. They are both present in A5 and C afferents,
and all are expressed before birth in the human spinal cord. By 8-10 weeks' gestation,
SP, somatostatin and CGRP are present in the spinal cord, with enkephalin and VIP
appearing later. A further increase in peptide concentrations occurs at 28-30
weeks10'11, and again at birth.
7
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Figure 1.3: The distribution of substance P, enkephalin and vasoactive intestinal
peptide in the developing human spinal cord
From Marti E, et al. Ontogeny of peptide- and amine-containing neurones in motor,
sensory, and autonomic regions of rat and human spinal cord, dorsal root ganglia,








As with adults, activation of the sympathetic nervous system in response to pain
produces physiological changes characteristic of the 'fight or flight' state. Heart rate,
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blood pressure, and respiratory rate increase (See Section 1.4.2). There are also
changes in oxygen saturation, vagal tone, pupil dilatation, and palmar sweating.
1.2.3 Behavioural evidence
To the parents or carers, the most instantly obvious indication of acute pain in an
infant would be behavioural changes, such as crying, and facial and body reactions
(See Section 1.4.1). In persistent or chronic pain, behavioural changes may be more
subtle, e.g. disruption of sleep, feeding, and perhaps more unexpectedly, an unduly
quiet demeanour.
1.2.4 The memory
Although conscious memories of pain in early life may not be apparent, the human
body has its own inherent subconscious memory. It has been demonstrated that
infants develop an increased sensitivity to pain in later life, if exposed to unpleasant
stimuli as a newborn12. This 'memory' was described by Taddio et al in two studies
of pain reactions during subsequent routine vaccination of infants who had been
circumcised as newborns13'14. Compared with non-circumcised males, circumcised
males displayed higher behavioural pain scores and cried longer. In the second study,
the use of a local anaesthetic cream during circumcision attenuated this subsequent
exaggerated pain response14.
Animal research has supported this with the finding that lack of analgesia provision
results in an alteration of the neuronal pathways responsible for pain transmission in
the spinal cord, and a consequent hyperalgesia15. Anatomical changes such as
9
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abnormal sprouting of primary afferents, and hyperinnervation of cutaneous tissue,
are seen following tissue injury16"18. Rats who experienced neonatal pain had lower
pain thresholds, defensive withdrawal behaviour, and hypervigilance during
adulthood18'19.
1.3 Importance of pain in neonates
1.3.1 Physiological and clinical evidence - the stress response
The stress response is the term used to describe the hormonal and metabolic changes
that follow physical or psychological trauma. This may or may not be associated
with the experience of pain. Stress hormones, such as adrenaline, noradrenaline,
Cortisol, glucagon, aldosterone, thyroid-stimulating hormone, and growth hormone,
encourage catabolic activity and water retention. They simultaneously increase heart
rate, blood pressure, and cardiac output, and increase the body's metabolic rate. They
also cause hyperglycaemia by promoting the release of glucose from glycogen and
preventing its utilisation. Gastric and bowel function and motility are also impaired.
Lastly, stress hormones also impair immune function and are pro-coagulant.
Anand et al first showed in 1985 that neonates had the ability to mount an endocrine
and metabolic stress response to surgery20'21. In a seminal study in 1987, Anand et al
then proceeded to prove that this neonatal stress response was related to the
undertreatment of pain22. This randomised controlled trial showed that major
hormonal responses were significantly greater in infants who received only nitrous
oxide and tubocurarine for patent ductus arteriosus ligation, compared with those
who received fentanyl. The clinical importance of this was demonstrated in another
10
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randomised controlled trial in 1992, where neonates receiving deeper anaesthesia
were found to have a lower incidence of sepsis, metabolic acidosis, disseminated
intravascular coagulation and death23. Untreated pain therefore exacerbates tissue
injury, prevents healing, increases susceptibility to infection, prolongs hospitalisation
and increases the risk ofmortality.
1.3.2 Long-term impact on pain experience
Tied in with the body's physical memory of pain are the anatomical and behavioural
changes which take place when a neonate, particularly if premature, experiences pain.
As described in Section 1.2.4, even a single painful event has been shown to alter
subsequent pain behaviour13'14. Repetitive painful stimuli can result in a 'rewiring' of
pain pathways resulting in subsequent hyperalgesia or even allodynia. Premature
infants are more vulnerable to this, and ironically, they are more exposed to multiple
painful procedures in early life.
1.3.3 Compassion
Pathological consequences aside, the treatment and alleviation of pain are a basic
human right that should take place whatever the age of the sufferer24. This was
recently advocated in October 2004 by the IASP and the European Federation of the
IASP Chapters (EFIC), with support from the World Health Organisation (WHO)
(www.who.int)25. The statement was made during a one-day conference in Geneva. It
coincided with new recommendations by the Council of Europe in Strasbourg on
pain relief. One person in five suffers from moderate to serious chronic pain, and one
in three of these are unable or only with difficulty able to lead an independent life.
11
Chapter 1: General introduction
Chronic pain is a major threat to the quality of life worldwide, and will become more
so as the average age increases.
1.4 Assessment of pain in neonates
Quantifying pain in neonates is a challenge because they cannot verbally
communicate this subjective phenomenon. This inability to communicate pain
largely explains why healthcare professionals failed to recognise and treat pain
appropriately, and continue to fail to do so. In the last few decades, however, various
methods for identifying pain in neonates have been developed, though none on its
own proves adequate. More recently, attempts to improve neonatal pain assessment
have moved towards multi-dimensional scoring, involving a combination of
behavioural and physiological factors.
1.4.1 Behavioural measures
Behavioural measures represent the current mainstay of pain assessment in neonates
and there are many tools available (Table 1.1). They mainly comprise observations
of body movement, facial expression, and cry. In selecting a pain assessment tool,
the clinician must be aware that some tools have preliminary validity for infants of
certain age groups only, or are designed for use with specifically procedural or post¬
operative pain, or even for use only in ventilated infants (e.g. DSVNI26).
One difficulty with behavioural measures is that infants who are more ill or
premature may respond less vigorously to pain27. Although the behavioural response
to acute pain is easily recognised, features of chronic or persistent pain may be
12
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altogether different. Furthermore, medical treatment of the most severely ill infants
may warrant the use of a paralysing agent. The elimination of all voluntary
movement then precludes any behavioural assessment of pain.
13
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Table 1.1: Clinical assessment of infant pain
Measure and
author









































Preterm and Facial expression, body
full term movements, response to
neonates handling/consolability,
rigidity of limbs
Infants 1 to 7 Sleep facial expression, cry
months motor activity, excitability,
digit flexion, sucking, tone,
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Full term Crying, oxygen saturation,
neonates heart rate, blood pressure,
expression, sleeplessness
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full term movement, color, heart
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From Franck LS, Greenberg CS, Stevens B. Pain assessment in infants and children.
Pediatric Clinics ofNorth America 2000;47:487-512.
1.4.1.1 Body movement
An obvious reflex body reaction to pain is withdrawal, which occurs at the spinal
level39. Other signs of pain include limb flailing, back and neck arching, and
clenched fists. Body movement is relatively indiscriminate and a signal of overall
distress rather than definite pain. If the source of pain is easily identifiable, then
measurement of overall distress may be a better indicator of the impact of the pain
experience. However if the source of pain is unclear, then global distress may
confuse the assessment of pain40.
15
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1.4.1.2 Facial expression
The facial expression of pain is more specific and reliable than body movement41. It
is displayed as a grimace, which comprises a furrowed brow, eye squeeze, a
deepened nasolabial furrow, taut mouth, and cupped tongue (Figure 1.4). The most
sensitive indicators are the first three, and the most specific the last two. Using these
indicators, systematic measures of pain have been developed, such as the Neonatal
Facial Coding System30. Other pain assessment tools exist that incorporate facial
activity in their scoring (Table 1.1). However, in preterm infants with persistent pain,
classic descriptions of frozen facial appearance and behaviour may not be as
obvious42.
Figure 1.4: The facial expression of pain
QUIET SLEEP HEEL LANCE
QUIET/AWAKE HEEL LANCE
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1.4.1.3 Cry
Crying is an important form of communication for the infant. It serves to alert the
infant's carer of an infant's needs. It commonly accompanies a painful event but, as a
marker of pain, is not 100% sensitive and is even less specific. Some infants do not
cry following a painful incident, and crying is also used to indicate hunger and other
non-painful distress. Studies have attempted to delineate a particular 'pain cry' using
spectral analysis27, and duration of cry has been used as a measure of analgesia43"47.
As with other behavioural measures, cry is of limited use in the more severely ill
infants. Not only are they less likely to produce a cry27, but interventions such as
endotracheal intubation make it very difficult to assess crying. If cry is used,
healthcare professionals need to adjust their threshold for identifying pain based on it,
depending on the infant's severity of illness.
1.4.1.4 The Premature Infant Pain Profile
This infant pain assessment tool is the most widely validated in both preterm and
full-term infants for procedural pain37,48. It is a seven-indicator measure that
comprises behavioural, physiological, and contextual indicators (Table 1.2). The
PIPP has mainly been used to evaluate procedural pain, but has now been validated
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1.4.2 Physiological measures
Pain initiates the stress response which produces quantifiable changes in
physiological parameters. The same response may however be instigated by non-
painful stressors. Furthermore these changes in physiological parameters may not be
so apparent in chronic or persistent pain. Physiological measures do form part of
some infant pain assessment tools (Table 1.1).
1.4.2.1 Heart rate and heart rate variability
In term neonates, the resting heart rate is generally between 100 to 140 beats per
minute. A rise in heart rate is a well-recognised physiological response to a painful
event, even in the most preterm infant. Processes that modulate cardiovascular
function are closely related to those involved with pain reactivity50,51. Heart rate is
controlled via a continuous feedback system which maintains blood pressure and
central venous volume. This complex procedure involves the central nervous system,
the autonomic nervous system, metabolic activity, and peripheral chemoreceptors
and baroreceptors. States of arousal and physical activity also play a role. Hence
heart rate is rarely constant, and heart rate variability represents continuous fine-
tuning within the feedback system. Greater fluctuations in heart rate are thought to
signify a healthier individual having a better ability to respond to changing
environmental demands52. At rest, both parasympathetic and sympathetic influences
are tonically active, with parasympathetic effects predominating. Parasympathetic
output to the heart is linked rhythmically with the respiratory cycle, giving rise to
respiratory sinus arrhythmia. There is a transient increase in heart rate with each
inspiration, and subsequent decrease with expiration.
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Heart rate variability can be analysed using various approaches, two common ones
being in the time domain and in the frequency domain. An electrocardiogram signal
is first obtained, then intervals containing ectopic beats or artefact are discarded.
From the remaining normal beat series, the RR interval, or beat-to-beat interval, is
measured. Heart rate is then expressed as beats per minute, or heart period. Heart rate
variability can then be calculated either in the time domain or the frequency domain.
A heart rate time domain signal can provide information on successive interval
differences, in terms of their mean, standard deviation, or variance. In the frequency
domain, spectral analysis can be used to quantify heart rate variability. Variability
depends on the length of the selected heart rate epoch, increasing as the epoch
53
increases , making cross-study comparisons difficult. Measuring heart rate
variability in this manner is labour-intensive and mainly provides retrospective
information, thus limiting its use to research.
A proxy measure of heart rate variability can also be obtained from cotside
monitoring systems. Typically, the analysis of consecutive RR intervals takes place
automatically, and a second-by-second rolling average heart rate is displayed.
Variability is then calculated as the standard deviation of the heart rate54. Artefact is
handled by routinely discarding a small percentage of the highest and lowest RR
interval measurements. As this is performed universally, it results in some loss of
relevant variability and is therefore not as accurate as the gold standard. However, it
represents a more clinically applicable tool.
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Heart rate is relatively easy and inexpensive to measure, and hence can be a useful
adjunct in pain assessment. When used alone it can be difficult to interpret, as it is
confounded by numerous physiological, behavioural and developmental factors, as
well as illness, and medical or pharmacological treatment. For example, mean resting
heart rate in term infants increases during the first two months of life, then decreases
through subsequent infancy55'56. Heart rate variability does the opposite57'58. Preterm
infants have a higher mean resting heart rate than term infants, and heart rate
variability increases with postnatal age, but is lower at term compared with term-
born infants52'59'60. This may suggest maturational delay. Small for gestational age
term infants also have a higher heart rate compared to those appropriate for
gestational age61. Mechanical ventilation and respiratory distress syndrome affect the
heart rate frequency spectrum62'63, as do birth asphyxia and intraventricular
haemorrhage64.
As a marker of acute pain, most studies have used mean heart rate differences
between groups, from a baseline period through the painful stimulus to a recovery
period. Heart rate tends to increase after the stimulus, then declines again during
recovery65"68. Heart rate responses to pain increase with increasing gestational age65.
Heart rate variability decreases, with changes in the spectral pattern depending on the
noxious event68. The use of analgesia attenuates characteristic heart rate responses to
pain, for example using local anaesthesia during circumcision69"71 and opioids during
22*72*73
surgery ' ' . Similar results have been obtained with non-pharmacological methods,
such as soothing with the use of pacifiers and swaddling74.
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As a marker for persistent pain or distress, however, heart rate and its variability
needs further study. Meanwhile, there is a role for heart rate responses as part of
multi-dimensional pain assessment tools (Table 1.1).
1.4.2.2 Bloodpressure
Blood pressure typically responds in parallel with heart rate to a painful event,
reflecting an overall increase in sympathetic arousal7'. As with heart rate, changes in
blood pressure are not necessarily indicative of pain; for example, it may be affected
by care procedures76, medical treatment, or severe illness.
1.4.2.3 Oxygen saturation
Invasive procedures in premature infants have been shown to cause a decrease in
oxygen saturation and cerebral blood flow77.
1.4.3 Neurochemical measures
Faced with the challenges of using behavioural and physiological signs for assessing
pain, especially chronic or persistent pain, it is no surprise that neurochemical
measures have also been studied in-depth. Neurochemical measures have their own
limitations. They serve mainly as a research tool, and as yet have little immediate
bedside applicability. Nevertheless, if an adequately sensitive and specific
neurochemical marker of pain were to be discovered, there would be further
incentive to developing it for direct clinical use.
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1.4.3.1 Catecholamines
Hypothalamic activation of the sympathetic nervous system causes an increased
secretion of catecholamines from the adrenal medulla, and also the release of
noradrenaline from presynaptic nerve terminals. Multiple studies have shown that
21 23-78
neonates are indeed capable of mounting a catecholamine response to surgery " ' ,
• 22-23and that this response can be attenuated with the use of adequate analgesia ' ,
indicating that pain is almost certainly responsible. Similar responses have been
found in neonates undergoing non-surgical procedures, such as mechanical
ventilation79, chest physiotherapy and endotracheal suctioning80. In fact, neonates
. . "70
have been found to exhibit a more extreme catecholamine response than adults .
Factors which may confound the interpretation of catecholamine levels, include
81 • 82 • 83
hypoxia , and the use of dopamine and pancuronium , which have all been shown
to affect catecholamine secretion.
1.4.3.2 Cortisol
Cortisol is a potent glucocorticoid, accounting for 95% of endogenous glucocorticoid
activity. It has been studied relatively extensively in neonates. Plasma Cortisol levels
in infants are affected by stress, including the stress of birth84. The same studies
above that reported the presence of a catecholamine response to surgery in neonates
also showed that elevations in plasma Cortisol and other corticosteroids
22"23*78occurred" ' ' . Circumcision without anaesthesia can cause an increase in plasma
Cortisol85.
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1.4.3.3 Insulin
Insulin is a small protein with a molecular weight of 5808 Daltons, secreted by the
beta cells of the pancreas. It circulates mainly in an unbound form, and has a plasma
half-life of 6 minutes. Insulin secretion is affected variably in neonates following the
stress of surgery, making it less reliable as a marker of pain. In association with
• 90 91 9 9*78
surgery, it can be suppressed , unchanged' , or elevated ' . Insulin secretion is also
sensitive to certain amino acids, gastrointestinal hormones, glucagon, growth
hormone, Cortisol, progesterone and oestrogen.
1.4.3.4 P-endorphin and other spinal cord neuromediators
Opioid receptors exist within the central nervous system together with multiple
natural opioids. These include P-endorphin, met-enkephalin, leu-enkephalin and
dynorphin. P-endorphin is an opioid peptide of 31 amino acids which derives from
the same preprohormone that gives rise to adrenocorticotrophin (ACTH) and
melanocyte-stimulating hormone (MSH). It also serves as a marker of the stress
2V78
response in neonates ' .
Within the spinal cord are various other peptides and non-peptides that are involved
in nociception and anti-nociception (Table 1.3). They interact in a complex manner
to facilitate or inhibit the transmission of pain signals86. Some are detectable in
plasma or saliva, such as P-endorphin, somatostatin, and CGRP. Historically though,
it is SP and the other tachykinins which have been considered to hold a prominent
role in the neurobiology of nociception.
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1.5.1 Substance P (SP)
Substance P is an undecapeptide that was first described in 1931 by von Euler and
Gaddum87 as a pharmacologically active compound present in mammalian intestinal
and brain extracts. Its name was derived from the working terminology used to refer
to crude 'preparations' of the active material. Initially, SP was found to cause
contraction of intestinal smooth muscle and lowering of blood pressure. However,
the reliability of much of the research and literature available on SP before 1970 is
uncertain due to the impurity of samples caused by contamination by other
biologically active agents such as bradykinin.
1.5.1.1 Molecular structure and classification
A breakthrough came in 1970 when Chang and Leeman purified the peptide from
bovine hypothalamus extracts and determined the amino acid sequence88'89. SP is
classified as a member of the tachykinin family90'91 (Table 1.4). Tachykinins were so
named because they were noted to cause faster contraction of smooth muscle than
bradykinin. They are peptides which have a similar amino acid sequence at the
carboxyl terminus [-Phe-X-Gly-Leu-Met-NTE (X = aromatic or branched aliphatic
amino acid)] and share a common spectrum of biological activity. Although most of
the tachykinins initially discovered were of amphibian origin, there is now a
recognised spectrum of mammalian tachykinins which include neurokinin A,
neurokinin B, neuropeptide K and neuropeptide y.
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Chapter 1: General introduction
1.5.1.2 Biosynthesis and distribution
SP is derived from a single copy of the preprotachykinin-A (PPT-A) gene. The PPT-
A gene also encodes for other tachykinins apart from SP, including neurokinin A
(NKA), neuropeptide K and neuropeptide y92. The preprotachykinin-B gene encodes
for neurokinin B alone93. The PPT-A gene has seven exons that can be
interchangeably spliced into one of four messenger ribonucleic acid (mRNA)
transcripts: a, P, y94 or 595 (Figure 1.5). SP is encoded by exon 3, which is present in
all four transcripts. This suggests that SP would be more prone to being produced
whenever the PPT-A gene is expressed. Induction of the PPT-A gene is influenced
by many factors, including cyclic adenosine monophosphate (cAMP), cytokines96,
thyroid hormone97, gonadal hormones98, glucocorticoids99, lipopolysaccharide
(LPS)100, neuropeptides, neurotrophic factors and neuronal depolarisation. SP
production in the spinal cord and increased peripheral SP release appear to be
stimulated by peripheral inflammationl01'102(Table 1.5).
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From Harrison S, Geppetti P. Substance P. International Journal ofBiochemistry &
Cell Biology 2001 ;33:555-76.
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Table 1.5: The inhibitory and excitatory effects of various biochemical compounds





















SP was first found to be synthesised in ribosomes of small diameter perikarya of
dorsal root ganglia103. It is packed into storage vesicles and axoplasmically
transported to peripheral and central terminations104. Four times as much SP
accumulates peripherally compared to within the dorsal root105. Expression of SP and
its mRNA is widespread in both the central and peripheral nervous systems. SP
immunoreactivity has been detected not only in the spinal cord but also in the
telencephalon, diencephalon, mesencephalon, metencephalon, myelencephalon
(medulla oblongata), rhinencephalon, basal ganglia, hippocampus, amygdala,
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hypothalamus and pons106. The areas in the central nervous system with particularly
high concentrations of SP are the striatum, substantia nigra, hypothalamus and the
dorsal horn of spinal cord (Figures 1.6a, 1.6b, 1.6c and 1.6d). Its production has been
more recently detected in the gastrointestinal107, immune and haematopoietic
systems108, thus identifying a possible hormonal role for it. Many subsequent studies
have now shown that SP is present in various tissues in mammals.
Figure 1.6a: Locations of the striatum, substantia nigra and hypothalamus on a
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Figure 1.6b: Concentration of SP in the substantia nigra (in red) on a sagittal section
of a rat brain
Figure 1.6c: Locations of the striatum, substantia nigra and hypothalamus on a
coronal section of the brain (GP = globus pallidus, SN = substantia nigra, STN =
subthalamic nucleus)
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Figure 1.6d: Concentration of SP in the substantia nigra (in white) using the
MapAnalyzer Mapping Fluorescence Microphotometry System. Quantitative
immunohistochemical distribution of SP in a brain slice of an adult normal human
(male, age 50). Data were obtained from approximately six million regions in the
brain at 50-pm intervals. Conspicuously intense SP-like immunoreactivity was
observed in the internal segment of the globus pallidus. The immunoreactive
intensity in the internal segment of the globus pallidus was approximately twice as






From Sutoo D, et al. Quantitative imaging of substance P in the human brain using a
brain mapping analyzer. Neuroscience Research 1999; 35: 339-46.
In the central nervous system, the highest concentrations of SP immunoreactivity are
in the superficial dorsal horn of the spinal cord, in the substantia nigra, and in the
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medial amygdaloid nucleus10 'no. Here, SP acts fairly closely to the site of release. In
the periphery, where SP occurs mainly in small diameter sensory fibres and in the
gastrointestinal nervous system, it appears that SP has to diffuse through connective
tissue to reach structures expressing the NK1R.
In animal studies, SP has been shown to be present together with other neuropeptides
in projection neurones of visceral and taste pathways extending from the periphery to
the sensory cortex in the central nervous system"1. It appears that SP is present in
neuronal cell bodies in the peripheral nodose ganglion, then the solitary nucleus of
the medulla, followed by the parabrachial nucleus of the pons. However,
subsequently from the thalamus projecting to the cortex, the main neuropeptides are
cholecystokinin, enkephalin and somatostatin.
Further animal studies have shown that only approximately 20% of SP-containing
sensory neurones of cervical dorsal root ganglia also possess opiate receptors and
histamine receptors, indicating that nociceptors and non-nociceptive sensory inputs
may be biochemically heterogeneous, hence it is unlikely that SP is confined to only
having a role in nociception alone"2.
Enzymes involved in the metabolism of SP include neutral endopeptidase (NEP), SP-
degrading enzyme, angiotensin-converting enzyme (ACE), dipeptidyl
aminopeptidase IV, post-proline endopeptidase, cathepsin-D and cathepsin-E. The
most important ones are likely to be NEP and ACE113.
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1.5.1.3 Receptor interaction and biological activity
The principal receptor for SP is the neurokinin-1 receptor (NK1R), a G protein-
coupled receptor with seven transmembrane domains (Figure 1.7). It is derived from
a single copy gene located on human chromosome 2114. The neurokinin-2 and
neurokinin-3 receptors (NK2R and NK3R) bind preferentially to neurokinin A and
neurokinin B respectively115 although there is some cross-reactivity. Binding of SP to
NK1R evokes a signal transduction cascade and generates diacylglycerol and inositol
triphosphate (Figure 1.8). These in turn activate protein kinase C and lead to release
of intracellular calcium. NK1R can also mobilise cAMP and generate release of
arachidonic acid. Following this, the SP-NK1R complex is internalised to endosomes
where it dissociates. NK1R is recycled to the cell surface whilst SP is degraded.
NK1R can undergo reversible desensitisation to SP with prolonged exposure or high
concentrations.
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From Harrison S, Geppetti P. Substance P. International Journal ofBiochemistry &
Cell Biology 2001;33:555-76.
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Figure 1.8: Signalling systems stimulated by neurokinin-1 receptor activation
Signalling/effector systems stimulated by NK-1 receptor activation
• stimulation ol P, turnover via PLC, leading to Ca2* mobilization
from both intra- and extracellular sources (PTX-resistant)
• cAMP accumulation via stimulation of AC
• suppression of inward rectifier K* channels (PTX-resistant)
• opening of chloride channels (PTX-sensitive)
• arachidonic acid mobilization via PlAj (PTX-sensitive)
• mitogenic stimulation via regulation of gene expression ???
From Quinn JP. The stimulus and inducible regulation of the preprotachykinin-A
gene that encodes the neuropeptide substance P, and the consequences for
inappropriate expression. (http://www.liv.ac.Uk/neuro/members/Ouinn.J.htmn
High concentrations of SP-binding receptors are found in the olfactory bulb,
amygdalohippocampal area and the nucleus of the solitary tract116. Heavy
concentrations of receptors are observed in the septum, diagonal band of Broca,
striatum subiculum, hypothalamus, locus coeruleus, parabrachial nucleus and lobule
9 and 10 of the cerebellum. Moderate to low concentrations of receptors are observed
in the cerebral cortex, globus pallidus, raphe nuclei and the trigeminal nucleus, and
•WW* NH,
1. Substance P binding
«Vm/Vnh. 10 c protein-coupled
NK-1 receptor
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very low densities exist in most aspects of the dorsal thalamus, substantia nigra and
cerebellum. Comparisons of the SP-binding receptor distribution with SP peptide
levels indicate that in some areas of the brain there is a rough correlation between
peptide and receptor levels. However, in other brain areas (olfactory bulb, globus
pallidus and substantia nigra) there is little obvious correlation between the two.
In the spinal cord, it is now known that NKA also binds to the NK1R with equal
affinity to SP and induces intracellular changes of similar magnitude117. Noxious
stimuli in inflammatory conditions result in NKA-mediated nociception. Although
SP-mediated NK1R internalisation occurs at the site of termination of stimulated
nociceptors, NKA-mediated NK1R internalisation could also occur at more distant
sites. NKA is also found more evenly distributed throughout the dorsal horn
following a noxious insult118.
Antagonists for NK1R were first discovered in the 1960s with an analogue of
eledoisin which contained a D-amino acid"9. However, most of the early antagonists
were of limited use as they lacked oral bioavailability and central nervous system
penetration (Table 1.6). The development of later antagonists such as CP96345,
CP99994, RP67580 and others have opened new doors in the understanding of the
physiological roles of NK1R. The NK1R has been shown to be involved in pain120,
121 • 122 • 123 • • 124 • 125
hyperalgesia , depression and anxiety states , colitis , emesis and
arthritis126. From human studies, NK1R antagonists have been found to be more
effective in persistent pain states rather than acute pain, again reinforcing the
involvement of SP in persistent pain127.
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Table 1.6: NK1 and NK2 receptor antagonists


































The main peripheral effect of SP is to produce neurogenic inflammation, resulting in
vasodilation, plasma extravasation, leucocyte adhesion, smooth muscle contraction
and glandular secretion. However, micromolar concentrations of SP are required to
evoke plasma extravasation, whilst dermal C-fibres release only nanomolar
concentrations.
1.5.1.4 Role in nociception
Initial theories about SP as a 'pain transmitter' arose in the 1950s because of its
concentration in the dorsal rather than ventral roots of the spinal cord128. Since then,
numerous animal studies have shown that SP is released with NKA in vivo in
response to noxious peripheral stimulation. There is electrophysiological evidence to
show that SP can activate dorsal horn neurons129,130. Also, morphine and related
analgesics were found to inhibit SP release from sensory terminals in vitro131. Cells
which respond most sensitively to SP are also the ones which respond most strongly
to painful stimuli13 . From NK1R and NK2R antagonist studies, SP and NKA have
been implicated in the spinal nociceptive reflex133,134. SP and NKA are preferentially
involved in mediating moderate to intense pain, as opposed to mild pain, and they
play an important role in persistent pain caused by tissue injury1,0.
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Studies in human subjects indicate that SP has more to do with chronic pain
associated with inflammation than with acute pain such as angina135, labour pain136
and postoperative pain136. The majority of studies into SP and pain have been animal
studies, and what has been investigated in humans has given rise to conflicting
results. This is probably due to the existence of some cross-species variation in
tachykinin distribution and hence results from animal studies cannot necessarily be
extrapolated to humans. Further difficulties giving rise to conflicting results may be
due to sampling methods, and sample processing and analysis. The tachykinins are
rapidly degraded in plasma and saliva, hence adequate sample preservation is
required. Also, various methods of extracting peptide (with various degrees of
peptide recovery), and of assaying peptide, have been reported.
Thus with regard to chronic pain in human subjects, some researchers have shown
that SP decreases, e.g. plasma SP in chronic back pain'j7, and others that it increases,
e.g. plasma SP in chronic arthritic pain13 , cerebrospinal fluid (CSF) SP in various
painful spinal diseases139, and CSF SP in fibromyalgia140. Moreover, a study by
Nicolodi and Del Bianco141 showed that salivary SP in migraine and cluster headache
sufferers was at a level similar to controls during attacks, but at a lower basal level in
between attacks. SP may also have a role in increasing pain threshold and tolerance
locally142. In an interesting case report of congenital insensitivity to pain, there was
absence ofNK1R in the skin of the patient143.
More recently, Basbaum144 has proposed that persistent injury causes reorganisation
in the spinal cord circuitry which results in exacerbated pain, and that SP plays a part
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in this. SP is released by intense stimulation of somatic and visceral tissues by
various modalities, which would certainly manifest as severe pain. Inflammation
then contributes by increasing dramatically the numbers of nerve cells involved.
Furthermore, activation of NK1R at the spinal level contributes to the induction and
expression of opioid physical dependence145.
1.5.1.5 Gastrointestinal effects
SP was first found in the gastrointestinal system". SP is expressed in distinct neural
pathways in all the layers of mammalian gut as well as in the extrinsic primary
afferent nerve fibres innervating the gut vascular system146. Here, SP is likely to co-
mediate gut motility, secretory processes and inflammation together with other
enteric transmitters147. SP may also be involved in inflammatory bowel disease with
findings of increased SP in left-sided ulcerative colitis and increased expression of
NK1R in the gut vasculature and lymphoid system in ulcerative colitis and Crohn's
disease. NK1R is also upregulated in Clostridium difficile-induced
148
pseudomembranous colitis .
1.5.1.6 Influence on haematopoiesis, the immune system, and the inflammatory
response
The mechanisms by which SP links the neural-immune-haematopoietic axis are
summarised in reviews by Payan149 and Rameshwar108. SP is released by nerve fibres
in lymphoid organs and also produced by immune cells100'150. It is closely involved in
communication with other molecules such as cytokines and adhesion factors. This
network is the regulator of the inflammatory response, resulting in recruitment of
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polymorphonuclear leucocytes and subsequent infiltration by macrophages and T-
cells. Delineated functions of SP in the immune system include:
a) induction of cytokine production (which can in turn further induce NK1R
production),
b) stimulation of lymphocyte production,
c) enhancement of chemotaxis and phagocytosis,
d) induction of immunoglobulin production through B-cell interaction,
e) promotion of eosinophil migration, mast cell degranulation and histamine
release, and
f) regulation of tissue repair via increased fibroblast, smooth muscle cell and
endothelial cell proliferation.
It is probably through these processes that SP has its role in inflammatory conditions
such as arthritis, asthma and inflammatory bowel disease.
In a similar manner, SP regulates haematopoiesis in conjunction with other cytokines.
It can be found in marrow stroma as well as nerve fibres. Here, SP exerts a positive
influence on bone marrow in that it stimulates production of progenitor cells.
1.5.1.7 Effects on the central nervous system
The effects of SP on memory, reinforcement and brain dopamine activity are
outlined in a review by Huston et a/15'. SP appears to have a memory-promoting
effect in parallel with increased site-specific extracellular dopamine. This might
account for the impairment in associative functioning in some neurodegenerative
diseases. SP is also known to be involved in depression, nausea and vomiting, and
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new therapies for these problems are being developed in the form of NK1R
antagonists152'153. Aprepitant (Emend, Merck & Co., Inc.), the first of this class, was
recently approved by the United States Food and Drug Administration (FDA) for the
prevention of both acute and delayed chemotherapy-induced nausea and vomiting154.
More recently, the antagonist L759274 has been shown to be efficacious as an anti¬
depressant in a randomised, double-blinded placebo-controlled trial155.
1.5.1.8 The respiratory system and the Sudden Infant Death Syndrome
SP has been implicated in pulmonary inflammation'36, asthma157 and the sudden
infant death syndrome (SIDS)158'159. SP release in the airways can be induced by
noxious factors such as viruses and chemicals. The importance of SP in pulmonary
neurogenic inflammation was defined in an animal study by Bozic et a/160, in which
normal mice were compared with NKlR-knockout mice. The inflammatory response
stimulated by immune complexes in normal mice was absent in NK1R-knockout
mice, suggesting that SP is vital in the amplification of pulmonary inflammation
induced by immune complexes. This also implies that blocking the SP system could
be useful in preventing adverse effects of pulmonary inflammation, but then the
protective side of the inflammatory response might be compromised. Subsequent
studies using NK1R antagonists have shown that airway hyper-reactivity and
microvascular permeability can be abolished161'162.
Through its effect on smooth muscle contraction, SP has been found to cause
constriction of human bronchi in vitro and guinea pig airways in v/vo164. It has
been proposed that this is part of the axon reflex mechanism thought to be
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contributory to the pathophysiology of asthma. Damage to airway epithelium would
allow C-fibre afferent nerve endings to be exposed to irritant stimuli and hence
produce SP and other sensory neuropeptides, which in turn produce
bronchoconstriction157. SP also increases the tracheal secretion of epithelial and
glycoprotein-rich fluids, and induces the release of mediators such as prostaglandins
and nitric oxide from the airway epithelium157. High concentrations of SP have
resulted in inhibition of surfactant secretion from isolated type II pneumocytes in
animal models165.
Although the principal neurotransmitters involved in producing the respiratory cycle
are glutamate, gamma-aminobutyric acid (GABA) and glycine, SP has been found to
be a modulator by acting both centrally and on peripheral sensory receptors166. In the
central nervous system, SP enhances the respiratory cycle by increasing the
respiratory rate as well as tidal volume. SP release from carotid chemoreceptor
nerves also occurs in response to hypoxia. It has been postulated that SP may be
involved in the pathophysiology of SIDS and there have also been studies performed
into SP and brainstem gliosis in SIDS158'159.
1.5.1.9 Cardiovascular effects
Species variation exists in the expression of SP in the mammalian heart. SP appears
to have no direct effect on heart muscle, but is a potent vasodilator. The vasodilatory
responses are brought about via NK1R in large arteries, leading to nitric oxide
release from the endothelium167.
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1.5.1.10 Relationships with other hormones
There is a huge amount of literature about SP and its interactions with other
hormones. Its role in the hypothalamic-pituitary axis has been reviewed by Jessop et
al] . SP modulates luteinising hormone (LH) and follicle-stimulating hormone (FSH)
release and is in turn modulated by oestrogen. Similarly, SP promotes thyrotrophin
(TSH) release, and pituitary SP content is decreased by thyroxine and increased by
thyroidectomy. SP appears to centrally mediate the inhibition of ACTH release from
the anterior pituitary, probably by inhibiting corticotrophin-releasing hormone
production in the hypothalamus. Again, anterior pituitary SP is decreased by
adrenalectomy. SP also either stimulates or inhibits release of prolactin and growth
hormone in what appears to be a dose-dependent relationship.
1.5.2 Neurokinin A (NKA)
1.5.2.1 Molecular structure and receptor interaction
Spliced from the same gene that codes for SP (PPT-A gene), NKA is a decapeptide
and a tachykinin very closely related to SP (Table 1.4). It is also known as substance
K or neuromedin L. The term neurokinin was first used in 1960 to describe 'a
polypeptide formed during neuronal activity in man' but that this was one of the
tachykinins is unclear169. Purified from porcine spinal cord, the amino acid sequences
of NKA and NKB were formally determined in 1983 by separate research groups,
and they were shown to have 81% and 65% of the activity of SP respectively on
guinea pig ileum170"172. As early as June the same year, it was postulated that NKA
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acted on a different receptor to SP173'174 The separate NK2 receptor for NKA was
identified in 1987175.
1.5.2.2 Biological activity
NKA is generally co-synthesised, co-localised, and co-secreted with SP. It has
similar effects to SP in that it also causes smooth muscle contraction, hypotension,
bronchoconstriction and plasma extravasation176. However the variation in regional
distribution of SP, NKA and NKB in rat brain and spinal cord suggested that each
tachykinin has a specific physiological function177. NKA has a neurotransmitter role
in the spinal cord, seen both by a depolarising response measured from lumbar
ventral roots following NKA application178, and also on immunohistochemistry118'179.
Evidence that both SP and NKA were involved in the transmission of pain signals in
C-fibres in the spinal cord accumulated118'180'181.
It was therefore surprising to find that NK2R exists minimally in the spinal cord182.
There is, however, some cross-reactivity between the tachykinins and the NK
receptors. It was subsequently confirmed that NKA is a high-affinity ligand for the
NK1R but that it is a poor competitor for SP183. NKA does contribute to at least 50%
of the NK1R activation in the dorsal horn of the spinal cord and is an important
NK1R ligand in v/vo117'184. Furthermore, it has been demonstrated that SP and NKA
may have a synergistic effect on spinal cord excitability185. As detailed in Section
1.5.1.3, it seems plausible that it is NKA, rather than SP, which is responsible for
nociceptive information transmission in the spinal cord.
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1.5.3 Substance P and neurokinin A in infants
If little work has been done on SP and NKA in adults, even less has been studied in
neonates and infants. There are no in vivo studies on NKA in infants or children.
Most of the SP studies have been confined to in vitro experiments such as anatomical
mapping of SP dense areas in various parts of the body and post-mortem
investigations in SIDS as outlined above.
The most recent publication related to in vivo studies in children was on age-
dependent levels of neuropeptides (including SP) in normal children. The authors
attempted to describe normal values using cord blood from six full-term infants, and
peripheral blood from 41 children varying in age from 1 month to 21 years1"6. An
early study on CSF SP levels found that levels were 100 to 1000-fold higher in
fetuses and preterm infants than in adults187. A later study on CSF SP levels in 39
neurologically normal children showed that levels of SP and (3-endorphin peak in the
first year of life and subsequently decline188. Finally, plasma and CSF SP levels were
shown to be elevated in 70 children with seizure disorders189. Again, this study was
difficult to interpret as it had subjects ranging in age from 1 month to 18 years.
Focusing on infants, only one very brief paper into plasma SP levels in healthy term
and preterm babies has been produced190, but unfortunately the data are unhelpful for
the following reasons:
a) the gestation of the preterm group was reported to be < 37 weeks with no
lower limit defined nor subgroups considered,
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b) the investigations were performed any time after the third week of life and
results were plotted according to the infants' corrected gestational age (which
ranged from -4 to 63 weeks (0 being term)),
c) although the two groups were described as healthy babies, there were no
qualifications to this, which would be especially relevant in the preterm group,
and
d) there was very little description of the methods of sample collection,
preservation and analysis used and degree of consistency in this.
1.6 Aims and objectives of the current study
The aims of this research project were:
a) to develop radioimmunoassays for SP and NKA sufficiently sensitive to
detect the neuropeptides from neonatal microsamples of plasma and saliva,
b) to determine variations in SP and NKA with gestational and postnatal age,
c) to study whether plasma and saliva SP and NKA levels varied with persistent
pain in neonates, and could therefore serve as potential markers of pain.
Currently, no gold standard exists in the measurement of chronic or persistent pain in
newborn infants. It is therefore difficult, if not impossible, to establish which infants
are suffering persistent pain sufficient to be of physiological or psychological
importance. Yet it is important to try to develop a measure that could be reliable
enough to guide a clinician to treat chronic pain where warranted. The PIPP is the
only measure which has been validated for use in more persistent pain, i.e. post-
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operative pain, and is therefore the closest to a gold standard measure that is
available.
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2. DEVELOPMENT OF PEPTIDE EXTRACTION PROCEDURE
Peptide extraction is a prerequisite for most radioimmunoassays. Extraction serves to
purify the sample and to ensure that the matrix of the sample is as similar to the assay
standards as possible. This is particularly important if the antibody is not highly
specific. Sample extraction can be performed using various methods, e.g. liquid-
liquid phase extraction, solid phase extraction columns with various liquid mobile
phases, or high-performance liquid chromatography.
The main disadvantages of sample extraction include loss of sample, and it is often a
time-consuming process. Loss of sample can be minimised by fastidious
determination of the best procedure to extract a particular peptide. This involves
investigating different physical methods of peptide extraction, as well as different
variants within a method.
Materials used are detailed in Appendix A.
2.1 Determining the need for an extraction procedure
This is performed by serially diluting the raw samples to be analysed, e.g. plasma or
saliva, and measuring peptide concentrations within an assay. If the antibody is
specific enough for the peptide in question, the serial dilution of samples will yield a
corresponding serial reduction in measured peptide. If the antibody is cross-reacting
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significantly with a matrix component, there will not be a serial reduction in
measured peptide. For choice of antibody, see Section 3.1.
Pooled plasma and saliva samples taken from adult volunteers were spiked with a
known concentration of SP standard and serially diluted 1:1 with assay buffer. Each
dilution was assayed in quintuplicate. Measured SP concentrations are tabulated
below (Table 2.1).
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Measured SP concentration (pmol/L)
Mean ± 1SD
Plasma 1 207.9 ± 17.6
1:2 118.0 ±3.9
1:4 54.0 + 2.0
1:8 32.8 ±3.4
1:16 18.6 ±8.0






When these results are displayed graphically, it is seen that serial dilutions of plasma
and saliva samples spiked with SP do not yield a serial reduction in measured peptide
when assayed directly (Graphs 2.1 and 2.2). This indicates that the antibody does
cross-react with a matrix component and hence sample extraction is warranted. This
is further confirmed in Section 2.2.1.
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Graph 2.1: Direct assay ofwhole plasma spiked with SP and serially diluted
240
SP dilutional factor
♦ Actual serial dilution
measurement
• ■ - Expected serial dilution
measurement
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Graph 2.2: Direct assay ofwhole saliva spiked with SP and serially diluted
• -Actual serial dilution
measurement
- ■ • - -Expected serial dilution
measurement
2.2 Liquid phase extraction (LPE) procedure
Parris et al]17 described a liquid phase extraction procedure developed by Yanaihara
et alm and recommended by the commercially produced SP radioimmunoassay kit
produced by Incstar Corp., Stillwater, Minnesota, USA. This extraction method
reportedly yielded a high percentage peptide recovery (Appendix B).
2.2.1 Specificity of peptide recovery using serial dilution
As in Section 2.1, serial dilution of pooled plasma and saliva samples spiked with SP
standard was performed. Half of each dilution underwent LPE. The other half was
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assayed directly, i.e. unextracted, and the corresponding results displayed. The
results are shown in Table 2.2, and Graphs 2.3 and 2.4.
Table 2.2: SP concentrations in serially diluted plasma samples measured by
radioimmunoassay following liquid phase extraction versus no extraction




Plasma 1 34.216 ±0.65 136.015 ± 10.5
1:2 17.481 ±0.68 103.75 ±8.66
1:4 7.108 ±0.63 58.467 ±2.15
1:8 2.426 ±0.21 31.727 ±0.13
Saliva 1 38.599 ± 0.74 72.255 ± 1.9
1:2 19.952 ±2.99 36.081 ± 1.43
1:4 11.266 ±5.25 21.017 ± 1.78
1:8 6.789 ± 1.16 10.813 ±0.0
SPLEFA16
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Graph 2.3: SP concentrations in serially diluted plasma samples measured by
radioimmunoassay following liquid phase extraction versus no extraction
♦ - Unextracted plasma
(measured)




- - -X- - - Extracted plasma
(expected)
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Graph 2.4: SP concentrations in serially diluted saliva samples measured by
radioimmunoassay following liquid phase extraction versus no extraction
80




—«— - Extracted saliva
(measured)
- - <* - -Unextracted saliva
(expected)
- - -X- - - Extracted saliva
(expected)
SP recovery for the same samples were as follows:
Table 2.3: SP recovery
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These results confirmed that sample extraction was essential for plasma samples as:
i) 'recovery' of SP was in excess of 100% (indicating antibody cross-reactivity
with a matrix component)
ii) serial dilution of plasma samples did not yield a serial reduction in measured
SP concentration when not extracted, and
iii) the measured SP concentration of plasma was four times higher when not
extracted compared with extracted samples.
For saliva samples, it may appear at first glance that extraction is not vital, as serial
reduction in measured SP concentrations is achieved. However, as with plasma, the
unextracted samples yielded almost double the measured SP concentrations of
extracted samples, indicating significant matrix cross-reaction once again.
Extraction for both plasma and saliva samples was therefore determined to be a pre¬
requisite for subsequent SP and NKA radioimmunoassay.
2.2.2 Determination of percentage recovery using 'hot' plasma and saliva
The degree of peptide recovery following liquid phase extraction was first assessed
crudely using 'hot' plasma and saliva, i.e. spiked with equal volumes of 1 5I-SP to
approximately 6000 cpm. The samples were extracted using the method described
above (Appendix B), and extracts and protein precipitates counted separately at the
end of the procedure to identify where peptide losses occurred, if any. Table 2.4
shows percentage recovery in the extracts at the end of the liquid phase procedure.
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Table 2.4: Percentage recovery from liquid phase extraction procedure (Yanaihara)
using 'hot' plasma and saliva samples
Matrix Matrix volume Extract recovery Mean extract recovery
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The liquid phase extraction procedure therefore looked promising, with relatively
good recovery yields, though not as high as claimed in the Yanaihara publication191.
There was a marked difference in recovery between plasma and saliva samples. The
residual counts that were lost were in the protein precipitate formed in the first step
of the extraction. Plasma has more protein than saliva and hence yielded larger
precipitates. The mean percentage of total counts present in the protein precipitates
were 17.46% for plasma and 5.07% for saliva. Using this liquid phase extraction
procedure, significant amounts of peptide were therefore not being extracted, but lost
in protein precipitation.
2.2.3 Determination of percentage recovery using 'cold' plasma and saliva
The experiment was subsequently performed using plasma and saliva spiked with
100 pmol/L of SP standard instead of l2:>I-SP (i.e. 'cold' plasma). The samples then
underwent liquid phase extraction and SP concentrations were measured by
radioimmunoassay. Table 2.5 shows percentage recovery in the extracts. The original
SP concentrations in the plasma and saliva samples without spike added were
represented by x and y pmol/L respectively. In the spiked samples, the volume of
spike used was 20% of the total pre-extraction sample volume. Hence the original SP
concentration in the spiked samples is represented by 0.8x+100 and 0.8y+100
pmol/L respectively for plasma and saliva.
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Table 2.5: Percentage recovery from liquid phase extraction procedure (Yanaihara)
using 'cold' plasma and saliva samples measured by RIA


































90.06 } 87.95 ± 5.9
77.78
91.83 J
Spiked saliva 0.8y+100 88.571 72.28 x
0.8y+100 94.448 78.16




The recovery in plasma samples was comparable to that achieved with 'hot' plasma
samples. However, the recovery with saliva was much poorer than with 'hot' saliva
samples.
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2.3 Solid phase extraction (SPE) procedure
Having achieved unsatisfactory peptide recovery with liquid phase extraction, the
efficiency of solid phase extraction was investigated. In solid phase extraction, the
sample is passed through a column (the solid phase), during which time peptides
bind with the column matrix via ionic interactions. The column is then washed of
residual plasma. Subsequently, the peptides bound to the column matrix are released,
or eluted, by a mobile phase (eluant) which reverses the ionic interactions. The
resultant eluate is collected, dried, and subsequently assayed for the required peptide.
As such, various solid phase columns exist, differing in the matrix component
depending on the type of peptide or other molecule to be extracted. An ideal column
has a high affinity for the peptide of interest, and the corresponding ideal eluant must
be able to elute the peptide from the column to completion. In addition, the wash
used in between must not be able to elute the peptide from the column.
Various SPE column manufacturers were contacted to obtain information on which
types of column would be most suitable for the extraction of tachykinins. Samples
were provided with which to run preliminary extractions to determine column
suitability.
2.3.1 Comparison between C8 and CI 8 SPE columns
In the first instance, the columns investigated were C8 and C18 types as they were
most suitable for small peptides. Two ml of assay buffer spiked with approximately
1 J c
2250 cpm of I-SP was run through each column type in duplicate, following the
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extraction procedure recommended by Euro-Diagnostica (Appendix C). Loss of
peptide during the extraction procedure was determined by measuring gamma counts
in the post-extraction samples and the column matrix, as well as the eluate. The
results are tabulated below.
Table 2.6: Source of peptide losses during solid phase extraction with C8 versus CI 8
columns
Column type % of pre-extractlon counts Total %
Post-extraction Retained on Eluate
plasma column recovery
C18MF 200 mg 5.2 110.4 4.9 120.5
CI8 MF 200 mg 5.4 111.6 4.3 121.3
C8 EC 100 mg 23.1 8.6 74.9 106.6
C8 EC 100 mg 61.6 5.6 44.8 112.1
SPSE4
From this, it could be seen that the residual post-extraction sample contained more
SP after passing through C-8 columns, indicating that these columns had a lower
affinity for SP and hence were unable adequately to extract the peptide from the
sample in the first stage. Conversely, C-18 columns appeared to have a high
extraction ability for SP, leaving little in the post-extraction sample. However, it
became clear from this experiment that although the C-18 columns extracted the
peptide, the eluant used was ineffective in the last stage of the extraction procedure.
A different eluant was required.
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2.3.2 Comparison between different CI8 SPE columns
Five different CI8 SPE columns were tested for SP recovery using 'hot' plasma
spiked with equal volumes of 125I-SP to approximately 8000 cpm. The mobile phase
according to Fehder was used (Appendix D). Table 2.7 shows percentage recovery
from various components of the procedure.
Table 2.7: Percentage recovery of 125I-SP from various components of CI8 SPE
procedure




Isolute C18 NEC 50 mg 75.1 20.9 3.1 99.1
Isolute CI8 MF 200 mg 64.6 10.2 11.0 85.8
Varian Bond-elute CI8 OH 100 mg 89.1 11.4 100.5
Phenomenex Strata C18 M 50 mg 88.8 13.8 102.6
Isolute PRS 50 mg 7.4 25.3 60.0 92.7
SPSECC
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The Isolute CI8 NEC, Varian Bond-elute C18 OH, and Phenomenex Strata CI8 M
yielded the highest recoveries with 'hot' plasma. The Isolute PRS was not evaluated
further as it yielded a very poor eluate recovery, with corresponding high losses of
SP in the post-extraction sample. This was replaced with the Varian CI8 50 mg in
the next stage.
Five CI8 SPE columns were then tested for SP recovery using 'cold' plasma, spiked
with 50 pmol/L of SP standard. Another five columns were simultaneously tested
using 'cold' saliva. To assess recovery, plasma and saliva from the same pool, but
without any addition of standard, were also extracted to obtain concentrations of
endogenous peptide recovered. As with 'hot' plasma, the mobile phase according to
Fehder was used (Appendix D). Table 2.8 shows the percentage recovery for SP in
plasma and saliva for the different columns.
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Table 2.8: Percentage recovery for SP in plasma and saliva for different CI8 SPE
columns
Manufacturer SPE column Sample SP Percentage
content (pmol/L) recovery (%)
Plasma
Isolute C18 NEC 50 mg Endogenous 3.964
With spike 46.989 86.1
Isolute C18MF 200 mg Endogenous 4.282
With spike 40.852 73.1
Varian Bond-elute C18 OH 100 mg Endogenous 5.887
With spike 53.392 95.0
Phenomenex Strata C18M50 mg Endogenous 5.987
With spike 58.733 105.5
Varian Bond-elute CI8 50 mg Endogenous 3.232
With spike 27.380 48.3
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Manufacturer SPE column Sample SP Percentage
content (pmol/L) recovery (%)
Saliva
Isolute CI8 NEC 50 mg Endogenous 2.716
With spike 51.509 97.6
Isolute C18MF 200 mg Endogenous 2.874
With spike 29.843 53.9
Varian Bond-elute C18 0H 100 mg Endogenous 2.703
With spike 51.869 98.3
Phenomenex Strata C18M50 mg Endogenous 3.297
With spike 48.373 90.2
Varian Bond-elute CI8 50 mg Endogenous 2.538
With spike 50.252 95.4
SPSEFA5
The Isolute CI8 MF yielded generally poor recovery for both plasma and saliva. The
Varian Bond-elute CI8 showed good recovery for saliva, but was very poor for
plasma. The Phenomenex Strata CI8 M demonstrated an extraordinary plasma
recovery of 105%, and previously 103% total recovery with 'hot' plasma. This was
deemed unsatisfactory as peptide appeared to be 'manufactured' by the columns, i.e.
more was detected than was originally spiked. After the Phenomenex column, the
Isolute CI8 NEC and Varian C18 OH gave the best recoveries.
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2.3.3 Comparison between different mobile phases
Although the mobile phase according to Fehder was used for initial SP recovery
experiments and appeared to be effective, it performed far less well with NKA. Three
C18 SPE columns each were tested with plasma and saliva spiked with 100 pmol/L
NKA standard. To assess recovery, plasma and saliva from the same pool, but
without any addition of standard, were also extracted to obtain concentrations of
endogenous peptide recovered. Table 2.9 shows the percentage recovery for NKA in
plasma and saliva for the different columns.
70
Chapter 2: Development ofpeptide extraction procedure
Table 2.9: Percentage recovery for NKA in plasma and saliva for different C18 SPE
columns using the Fehder mobile phase
Manufacturer SPE column Sample NKA Percentage
content (pmoI/L) recovery (%)
Plasma
Isolute C18NEC50mg Endogenous 8.420
With spike 12.620





Isolute C18NEC50mg Endogenous 52.812
With spike 63.640





This was disappointing as both SP and NKA peptides needed to be extracted during a
single extraction procedure. The Fehder mobile phase obviously worked well for SP
but not for NKA. A new mobile phase needed to be investigated. The extraction
procedure was therefore repeated with the mobile phase according to the Peninsula
kit insert (Appendix E). Results are shown in Table 2.10.
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Table 2.10: Percentage recovery for NKA in plasma and saliva for different CI8
SPE columns using the Peninsula mobile phase
Manufacturer SPE column Sample NKA Percentage
content (pmol/L) recovery (%)
Plasma
Isolute C18NEC50mg Endogenous 14.225
With spike 99.292






Isolute C18NEC50mg Endogenous 18.230
With spike 106.330
Varian Bond-elute C18OH100mg Endogenous 23.437
With spike 107.820
NKASEFA2
The Peninsula mobile phase produced much higher NKA recovery than the Fehder
mobile phase. The effect of the Peninsula mobile phase on SP recovery was therefore
also tested using 'cold' plasma spiked with 50 pmol/L of SP standard. Results are
shown in Table 2.11.
Table 2.11: Percentage recovery for SP in plasma and saliva for different CI8 SPE
columns using the Peninsula mobile phase
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Manufacturer SPE column Sample SP Percentage
content (pmol/L) recovery (%)
Plasma
Isolute C18NEC50mg Endogenous 2.468
With spike 38.226





Isolute C18NEC50mg Endogenous 7.059
With spike 48.425





The Peninsula mobile phase was therefore deemed to be the most suitable for SPE of
both SP and NKA from the same sample. With the Peninsula mobile phase, the
Isolute CI8 NEC column produced a higher percentage recovery compared with the
Varian Bond-elute CI8 OH. The Isolute CI8 NEC column, coupled with the
Peninsula mobile phase, was therefore used for all subsequent sample extractions.
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2.4 Discussion
Peptide extraction was found to be required for the analysis of SP as the 'recovery' of
SP was in excess of 100% with non-extracted samples (Section 2.2). This indicated
that the antibody was cross-reacting with a matrix component. Furthermore, serial
dilution of non-extracted plasma and saliva samples did not yield a serial reduction in
measured SP concentration, again indicating that cross-reactivity with a matrix
component was occurring (Section 2.1). Finally, the measured SP concentration in
non-extracted plasma samples was four times higher than extracted plasma samples,
and in non-extracted saliva samples was almost twice as high as extracted saliva
samples (Section 2.2). This was in accordance with findings published by Joyce et al
192, who discovered that unextracted plasma and synovial fluid gave higher
measurements than extracted samples, and queried the accuracy of other published
reports on plasma SP variations with clinical conditions where sample extraction had
not been performed.
The Yanaihara liquid phase extraction procedure seemed promising initially, with
relatively high recoveries of 81% for plasma SP and 97% for saliva SP using 'hot'
plasma and saliva (Section 2.2.2). It was identified that the larger losses for plasma
SP seemed to occur in the protein precipitates generated by the extraction procedure.
The liquid phase extraction procedure was then repeated with 'cold' plasma and
saliva, as this would test the compatibility of the post-extraction matrix with the
radioimmunoassay. Plasma SP recovery was maintained at 88%, but recovery with
saliva SP was much poorer at 68% (Section 2.2.3). Hence, solid phase extraction was
investigated as an alternative.
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The first stage in the research of solid phase extraction for SP was to determine
which type of column was best for the peptide. C18 columns were found to be more
efficient than C8 columns at extracting the peptide (Section 2.3.1), and in particular,
the Isolute CI8 NEC and Varian Bond-elute CI8 OH columns yielded the highest
recoveries (Section 2.3.2). The next stage was to find a mobile phase that would
facilitate good extraction of SP from the plasma and saliva samples by the columns,
and would then finish by being able to elute the extracted peptide completely from
the columns. Commercially available kits exist for SP radioimmunoassay, but the
current investigations have shown that extraction procedures described in the kits do
not always produce good recoveries. For example, the extraction procedure
recommended by Euro-Diagnostica (Appendix C) resulted in good extraction of SP
by the CI8 column, but the eluant suggested was then incapable of eluting the
peptide from the column (Section 2.3.1). The Euro-Diagnostica kit was therefore
being marketed with a recommended extraction procedure that would yield
negligible SP recovery.
Following this discovery, the Fehder mobile phase (Appendix D) was used, which
closely resembled the Euro-Diagnostica mobile phase, apart from the use of acidified
acetonitrile instead of non-acidified methanol as the eluant. This change in eluant
yielded a much improved recovery of plasma and saliva SP (>85%) from the CI8
columns (Section 2.3.2). However, the same mobile phase produced extremely poor
recovery of plasma and saliva NKA from the same columns (<60%) (Section 2.3.3).
This was disappointing as both SP and NKA needed to be extracted from the same
sample during a single extraction procedure.
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A third mobile phase, from Peninsula, was therefore tested. The eluant remained as
acidified acetonitrile but the rest of the mobile phase was different (Appendix E).
The method was slightly modified in that the elution was conducted under gravity
only, whereas the original method stated that a light vacuum pressure might be
applied to the columns. The Peninsula mobile phase produced a much higher NKA
recovery than the Fehder mobile phase (>85%), and a nonetheless satisfactory
recovery for SP recovery (>70%) (Section 2.3.3). With the Peninsula mobile phase,
the Isolute CI8 NEC column also produced better recoveries than the Varian Bond-
elute C18 OH column.
As a consequence of the multiple investigations documented above, the final
extraction procedure used was the Peninsula mobile phase coupled with the Isolute
CI8 NEC columns.
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3. DEVELOPMENT OF SUBSTANCE P AND NEUROKININ A
RADIOIMMUNOASSAYS
A radioimmunoassay is based on relatively simple principles. A fixed concentration
of antibody is incubated with step-wise increasing concentrations of antigen
(standard). Then a fixed concentration of radioactively-labelled antigen (tracer) is
added. This binds the residual antibody sites not occupied by the standard, and tracer
and standard will compete for available antibody sites until an equilibrium is attained.
The bound fraction of antibody is then precipitated out and unbound antigen
removed. The bound fraction is measured in a gamma counter and the count of
labelled antigen is inversely related to the concentration of standard. From these
results, a standard curve is constructed from which unknown antigen values can be
calculated.
Commercial radioimmunoassay kits exist for both SP and NKA. However, the
IDS/Euro-Diagnostica SP kit requires 2 ml of plasma for the extraction procedure, a
small volume for an adult subject, but an unacceptably large volume for many
neonates. In-house radioimmunoassays therefore needed to be developed, with
increased sensitivities, to measure SP and NKA concentrations from neonatal
microsamples.
Materials used are detailed in Appendix A.
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3.1 Choice of antibody
Antibody to SP exists from various sources. However, as NKA was also being
studied, it was imperative that no cross-reactivity occurred between the two assays.
Table 3.1 summarises the cross-reactivity patterns of different SP antibodies as
published by their manufacturers. Table 3.2 summarises similar results for NKA.
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Table 3.1: Cross-reactivity profiles for various commercially-available SP antibodies
Manufacturer
IDS/Euro- Sigma Assay Cayman
Diagnostica Cat No. Designs Cat No.
Cat No. A45 SI 542 Cat No. 583751
Batch SP-2-840530 90018/90118




Substance P 100% 100% 100% .100%
SP sulphoxide 103% 122% 85.9% 93%
SP 4-11 22% 175% 11.7% 97%
SP 7-11 <0.001% 0.96% 5.9% 30%
Neurokinin A 0.001% 0.2% 0.8% 2.7%
Neurokinin B 0.001% 0.2% 0.04%
Kassinin <0.001%
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Other SP antibodies exist for immunostaining and immunoblotting rather than use in
a radioimmunoassay, e.g. Diasorin, and manufacturers above.




Cat No. A57 Cat No. RIK7359
Batch YS6989
Rabbit host Rabbit host
Polypeptide Cross-reactivity (%)
Neurokinin A 100% 100%
NKA sulphoxide 72%




Substance P 0.1% 0.05%
Physalaemin 0.1% 0.02%
Bombesin 0.01%
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From the cross-reactivity profiles, it was decided that the SP antibody of choice was
from IDS/Euro-Diagnostica and the NKA antibody of choice was from Peninsula.
The published cross-reactivities were checked. Cross-reactivity with NKA in the SP
assay was 0% and cross-reactivity with SP in the NKA assay was 2%.
3.2 Optimisation of antibody concentration
Following the choice of antibody, the optimal antibody concentration was
determined for each assay. The more dilute the antibody, the more sensitive the assay
at lower peptide concentrations. However, this has to be balanced with the total
binding achieved.
Optimal antibody concentration was therefore investigated by running simultaneous
assays where the only difference was that of the antibody concentration added to the
assay. This was performed separately for SP and NKA. The results are tabulated
below (Tables 3.3 and 3.4). Percentage tracer bound over total is indicated by
%B/Tot and percentage tracer bound over reference by %B/Ref.
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Table 3.3: Determination of optimal SP antibody concentration to be added to assay
Antibody Total binding SP standard %B/Tot %B/Ref
concentration (%) (pmol/L)
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Antibody Total binding SP standard %B/Tot %B/Ref
concentration (%) (pmol/L)











Good differentiation between top and bottom standards was achieved with all SP
antibody concentrations. With a SP antibody concentration of 1:300, the assay was
insufficiently sensitive to differentiate SP concentrations <3.9 pmol/L. This was
improved with a SP antibody concentration of 1:400. Diluting SP antibody further to
1:500 resulted in a lack of differentiation between the lowest two standards. Hence
the ideal SP antibody concentration for use in the assay was 1:400.
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Table 3.4: Determination of optimal NKA antibody concentration to be added to
assay
Antibody Total binding NKA standard %B/Tot %B/Ref
concentration (%) (pmoI/L)
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Antibody Total binding NKA standard %B/Tot VoB/Ref
concentration (%) (pmol/L)











At all NKA antibody concentrations, good differentiation was achieved between the
top and bottom standards. More importantly, differentiation between the lower
standards was considered, as it was estimated that concentrations of NKA in infant
samples would be in this vicinity, based on published adult concentrations. At a
NKA antibody concentration of 1:50, poor differentiation was achieved at NKA
concentrations of <7.8 pmol/L. The assay increased in sensitivity for the 1:75
concentration, as adequate differentiation was demonstrated between NKA
concentrations of 3.98 and 7.8 pmol/L. This was further improved when NKA
antibody concentration was dropped to 1:100. However, at this concentration, total
binding dropped to 19.59%. The ideal NKA antibody concentration for use in the
assay was therefore 1:75.
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3.3 Optimisation of assay and sample volumes
The original SP assay used a sample or standard volume of 100 pi, antibody volume
of 200 pi and tracer volume of 200 pi. The original NKA assay required sample,
antibody and tracer volumes of 100 pi each. Following the determination of optimal
antibody concentrations, it was investigated whether similar assay sensitivities could
be preserved if the assay volume were to be halved (mini assay). This was preferable
as plasma and saliva samples obtained from infants are of a much smaller volume
than can be obtained from adults. Also, the same sample needed to be assayed for SP
concentration, NKA concentration, and Cortisol concentration to yield parallel results.
Tables 3.5 and 3.6 show comparisons between normal and mini SP and NKA assays.
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Table 3.5: Comparison between normal and mini SP assays
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Table 3.6: Comparison between normal and mini NKA assays
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Both mini assays showed drops in degree of sensitivity when compared to the
original assays. However, if 100 pi sample volumes were to be used in accordance
with the original assays, the majority of the neonatal microsamples would not be
sufficient for analyses of SP, NKA and Cortisol.
3.4 Comparison of Sigma and Peninsula SP standards
As there were different SP standards available, it was important to determine the
affinity between various standards within the in-house assay developed. Synthetic SP
(Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) was obtained from
Peninsula Laboratories Europe Ltd and Sigma Chemical Company. Details of each
standard are provided in the table below. It was expected that the Peninsula standard
would exhibit better affinity as the antibody used was raised against it.
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Table 3.7: Comparison between Peninsula and Sigma SP standards
Peninsula Laboratories Ltd Sigma Chemical
Company
Catalogue no. 7451 S6883
Molecular weight 1347.66 1347.63
HPLC purity 97.8% (TFA buffer system) 98%
99.2% (NaH2P04 buffer
system)
Capillary Single peak found Not stated
electrophoresis
Maldi mass 1348.90 Not stated
spectrometry
Peptide content 79.4% Not stated
The SP standards were then diluted identically and used in the same assay. Table 3.8
shows the percentage bound over total (%B/Tot) for the respective standards, and
Graph 3.1 shows the difference between the standards when plotted as percentage
bound over reference (%B/Ref).
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Table 3.8: %B/Tot for Peninsula versus Sigma SP standards in the same assay








Graph 3.1: Peninsula versus Sigma SP standard curves in the same assay
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The experiment was not repeated for NKA. Instead, the Peninsula NKA standard was
used routinely as the antibody was also from Peninsula.
3.5 Stability of Peninsula standard
For each assay, the SP standards used were prepared freshly from stock Peninsula SP
standard concentrate (5xlO"8M). The standards were prepared in polypropylene tubes
(See Section 4.1). The stability of the diluted standards was assessed by leaving them
in the polypropylene tubes for 24 hours at 4°C and repeating the assay to see whether
binding was affected (Table 3.9 and Graph 3.2).
92
Chapter 3: Development ofSP andNKA radioimmunoassays
Table 3.9: Comparison between fresh and 24-hour delayed SP standard curves
Assay type Total binding SP standard %B/Tot %B/Ref
(%) (pmol/L)
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Graph 3.2: Comparison between fresh and 24-hour delayed SP standard curves
After 24 hours, the diluted SP standards showed a change in binding and a variation
in the shape of the standard curve obtained compared to freshly prepared standards.
This stressed the importance of using freshly prepared standards for each SP assay
performed. The same principle was applied to the NKA assay without repetition of
the experiment.
3.6 Equilibrated versus disequilibrated assay
Radioimmunoassays are based on the principle of competitive binding between
peptide (as standard or endogenous) and tracer. When peptide concentrations exist in
small amounts, tracer addition can be staggered or delayed to facilitate binding of
peptide with antibody in the first instance. This is known as a disequilibrated assay.
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The assay for SP was compared in equilibration and disequilibration to see if
improved binding of standards, and hence increased sensitivity, could be achieved.
In the equilibrated assay, SP antibody, standard and tracer were mixed together.
After 24 hours, a second antibody was added to precipitate the bound fraction out.
After a further 24 hours, the supernatants were discarded and the precipitates counted
in a gamma counter. In the disequilibrated assay, SP antibody and standard were
mixed 24 hours in advance of tracer being added. The rest of the procedure was
identical. To allow direct comparison, the assays were done in parallel with the same
batch of antibody, tracer and standard (Table 3.10 and Graph 3.3).
Table 3.10: Comparison between equilibrated and disequilibrated SP assays
SP concentration %B/Ref
(pmol/L)
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Log SP concentration (pmol/L)
The results show that delaying the addition of tracer by 24 hours (disequilibrating the
assay) yielded a slightly better standard curve. The same principle was also applied
to the NKA assay without repetition of the experiment.
3.7 Evaluating different second antibodies
In the final step of a radioimmunoassay, the fraction of bound primary antibody is
separated out to be quantified so that the concentration of analyte can be determined
based on an inverse standard curve. A variety of separation methods exist, such as
adsorption with activated charcoal, or precipitation with a second antibody or
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polyethylene glycol (PEG). Two different second antibody precipitation methods
were evaluated, one using donkey anti-rabbit serum with normal rabbit serum
(DARS/NRS), and the other using cellulose (Sac-Cel®). The assays were
disequilibrated and done in parallel, with the only difference being the type of second
antibody used in the final step. Table 3.11 and Graph 3.4 show results for the SP
assay, and Table 3.12 and Graph 3.5 show results for the NKA assay.
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Table 3.11: Comparison between Sac-Cel (two volumes) and DARS/NRS in SP
assay





Sac-Cel assay 55.41 15.6 53.33 96.25





Sac-Cel assay 56.65 15.6 54.69 96.54
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Graph 3.4: Comparison between Sac-Cel (two volumes) and DARS/NRS SP
standard curves
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Table 3.12: Comparison between Sac-Cel and DARS/NRS in NKA assay
Assay type Total binding NKA standard %B/Tot %B/Ref
(%) (pmol/L)
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Graph 3.5: Comparison between Sac-Cel and DARS/NRS NKA standard curves
In both the SP and NKA assays, precipitation with either Sac-Cel or DARS/NRS was
equally effective. A volume of 400 pi of Sac-Cel yielded no benefit over a 100 pi
volume.
3.8 Quality controls
The projected inter-assay variation was determined from six assays each of SP and
NKA, at approximately 80%, 50% and 20% binding, i.e. the straight part of the
standard curve (Tables 3.13 and 3.14). This showed that inter-assay variation was
<8% for the SP assay and <10% for the NKA assay. However, it was subsequently
found that the median plasma SP and NKA concentrations in newborn infants were
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detected to be lower, i.e. 1.7 pmol/L and 6.0 pmol/L respectively. The inter-assay
variation at these low concentrations was calculated to be <12% for the SP assay and
<15% for the NKA assay.
Table 3.13: Inter-assay quality control values for six SP assays
Quality control value (pmol/L) 7.8 31.2 125 1.95
80% 50% 20%
8.08439 28.59886 148.79678 1.99785
8.97903 29.77500 129.39935 1.47880
8.46620 28.82507 135.37430 1.99845
7.28155 31.23256 127.55523 1.87751
7.93201 28.15454 125.98616 1.77280
8.45007 29.44108 122.32207 1.60937
Mean 8.19888 29.33785 131.57232 1.78913
SD 0.57776 1.09553 9.47384 0.21170
%CV 7.0 3.7 7.2 11.8
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Table 3.14: Inter-assay quality control values for six NKA assays
Quality control value (pmol/L) 15.6 62.5 250 7.8
80% 50% 20%
16.46735 59.64672 251.45707 6.06700
12.45740 61.29907 241.85910 9.38516
13.55277 57.93835 273.13021 8.73577
14.40160 67.22630 236.20090 8.28402
15.53646 66.68324 254.28288 7.06139
14.44818 63.75661 269.11434 7.98407
Mean 14.47729 62.75838 254.34075 7.91957
SD 1.41587 3.77910 14.59087 1.19328
%CV 9.8 6.0 5.7 15.0
3.9 Discussion and final SP and NKA radioimmunoassay protocols
As neither SP nor NKA had previously been studied in neonates, the
radioimmunoassays required development for use with neonatal microsamples. Ideal
antibody concentrations were found to be 1:400 for the SP assay and 1:75 for NKA,
with total binding being approximately 39% and 28% respectively (Section 3.2). To
permit analyses of both SP and NKA from one neonatal microsample, assay volumes
needed to be halved. This was accompanied by inevitable drops in sensitivities of
both assays (Section 3.3). However, the quality control results given in Section 3.8
are for the mini assays.
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Further investigation of the assay procedure showed that freshly prepared standards
were required, as the shape of the standard curve changed when standards were left
for 24 hours. This occurred despite the standards being in polypropylene tubes (See
Section 4.1) and was possibly due to some interaction between the peptide and tube.
Disequilibration of the assay was performed as this yielded a slightly better standard
curve (Section 3.6). It is acknowledged that the difference between the equilibrated
and disequilibrated standard curves is mainly seen in two points. Disequilibration of
the assay did not however result in any deterioration of the standard curve and was
therefore used because the peptide concentrations existed in small amounts.
Evaluation of different second antibodies showed equally effective precipitation with
either Sac-Cel or DARS/NRS (Section 3.7). Sac-Cel was used in the final assay
protocols as the availability was more reliable than that of the DARS/NRS.
Following the development of various aspects of both SP and NKA
radioimmunoassays, the final protocols used are detailed in Appendix F.
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4. SAMPLE COLLECTION
Materials used are detailed in Appendix A.
4.1 Evaluation of tube type
Certain peptides are recognised to have an affinity for polystyrene, hence using
polystyrene equipment during sample collection and processing would affect peptide
concentrations recovered. The purpose of the following study was to examine the
affinity of SP and NKA for polystyrene.
50 pi of stock SP standard (5xl0~8M) was diluted in 4950 pi assay buffer to yield a
top RIA standard of 500 pmol/L. Serial 1:2 dilutions of the top standard down to 0.98
pmol/L were performed to construct a standard curve for RIA. Standards were made
up in polypropylene tubes and vortex mixed. Half a volume of each standard (1 ml)
was then transferred to an identical polystyrene tube and vortex mixed.
The polystyrene standards were then evaluated in an assay using the polypropylene
standards to construct the standard curve. Table 4.1 shows measured SP
concentrations of the polystyrene standards against expected SP concentrations.
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Table 4.1: SP concentrations of polystyrene standards against polypropylene SP
concentrations
Expected SP Measured SP Percentage recovery












Clearly, the use of polystyrene tubes affected the concentration of SP in all the
diluted standards. In the lowest two standards, SP was undetectable after only brief
contact with polystyrene. This was most likely due to adherence of the small peptide
to polystyrene. It was therefore vital that all the materials involved in sample
collection, peptide extraction and peptide assay were made of polypropylene, and not
polystyrene.
106
Chapter 4: Sample collection
4.2 Effect of time and ice on sample integrity
The effect of time elapsed and use of ice between sample collection and
centrifugation/freezing were assessed separately for endogenous and exogenous SP
and NKA.
4.2.1 Endogenous tachykinin recovery
15 ml blood was obtained from one adult subject by venepuncture and divided into
ten aliquots of 1.5 ml each. Aliquots were in polypropylene microtubes containing
freeze-dried aprotinin and ethylenediaminetetraacetic acid (EDTA) (50 pi each). Five
microtubes of whole blood were kept on wet ice throughout while the other five were
at room temperature. At the times specified in the table below, one microtube from
each group was spun in a microfuge for 1 minute, the plasma was decanted into a
corresponding polypropylene microtube containing freeze-dried aprotinin and EDTA,
and then frozen at -20°C.
Tachykinins were extracted from 0.5 ml plasma as described in Appendix E and
assayed for SP and NKA. Table 4.2 shows concentrations of endogenous SP and
NKA recovered at the various time periods.
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Table 4.2: Effect of time and ice on endogenous plasma tachykinins
Time Substance P (pmol/L) Neurokinin A (pmol/L)
(min) Ice No ice Ice No ice
0 12.132 10.384 27.221 26.433
5 13.256 10.119 28.581 27.913
10 13.157 10.258 25.492 28.895
20 14.120 8.071 35.266 33.134
60 14.066 5.129 30.129 23.387
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4.2.2 Exogenous tachykinin recovery
50 ml blood was obtained from one adult subject by venepuncture and immediately
mixed with 25 pi of stock SP standard (5xl0~8M) and 25 pi of stock NKA standard
(1x10~7M). Aliquots were prepared as described in Section 4.2.1, and the rest of the
experimental procedure followed. Table 4.3 shows concentrations of SP and NKA
recovered at the various time points. Graphs 4.1 and 4.2 show the data displayed for
SP and NKA respectively.
Table 4.3: Effect of time and ice on exogenous plasma tachykinins
Time Substance P (pmol/L) Neurokinin A (pmol/L)
(min) Ice No ice Ice No ice
0 24.263 20.768 54.442 52.866
5 26.511 20.238 57.161 55.825
10 26.314 20.516 50.983 57.789
20 28.239 16.141 70.531 66.267
60 28.132 10.258 60.257 46.773
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Graph 4.1: Effect of time and ice on endogenous and exogenous SP concentrations
in vitro
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Graph 4.2: Effect of time and ice on endogenous and exogenous NKA
concentrations in vitro
Time (min)
- - Endogenous - Ice —•— Endogenous - No ice
— -A- - Exogenous - Ice —■— Exogenous - No ice
These data show that SP and NKA concentrations remain stable in blood samples
that are collected into microtubes containing freeze-dried aprotinin and EDTA,
provided they are centrifuged, plasma decanted, and snap-frozen within 10 minutes
of collection, whether or not ice is used.
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4.3 Discussion and final collection procedure
Following the determination of best practice for sample collection, the final sample
collection procedure is detailed in Appendix G. It was found that SP concentrations
were reduced in assay buffer even after only brief contact with polystyrene (Section
4.1). Care was subsequently taken to ensure that all samples were collected, stored
and extracted in polypropylene tubes only. Interestingly, the peptide extraction
procedure described by Peninsula (Appendix E) stipulated that the eluant should be
collected in a polypropylene tube.
Section 4.2 showed that both endogenous and exogenous concentrations of NKA
remained stable in blood samples that were collected into microtubes containing
freeze-dried aprotinin and EDTA, as long as the samples were centrifuged, plasma
separated, and snap-frozen within 10 minutes of collection. NKA concentrations
were stable regardless of whether ice was used or not. Concentrations of SP also
remained stable if samples were processed within 10 minutes, but keeping the
samples on ice seemed to yield higher overall concentration values of SP, even in the
first sample processed immediately (i.e. with no contact time with the ice). The
longer the sample spent on ice, the higher the SP concentration measured, whereas
the samples not kept on ice showed a natural decline in SP concentration, as would
be anticipated from endogenous enzymatic degradation. The increase in SP
concentration on ice could possibly be due to chance variation in the blood sample
during division into aliquots, or a real effect of ice causing dissociation of SP from
albumin or other binding proteins, resulting in increased antibody interaction. ITence,
to avoid peptide losses from enzymatic degradation, the final Study Collection
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Procedure (Appendix G) stipulated that all samples should be kept on ice during
collection, and that the time from start of sample collection to freezing should be no
longer than 10 minutes.
The finding of the current study is supported by the work of Joyce et al192, who
confirmed that synthetic SP was degraded in a temperature- and time-dependent
manner when incubated with human plasma or synovial fluid. Using a cocktail of
protease inhibitors, this degradation was prevented without the use of ice.
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5. METHODOLOGY FOR SUBSEQUENT CLINICAL STUDIES
5.1 Aims
The development of in-house extraction and radioimmunoassay procedures for SP
and NKA (Chapters 3 and 4) allowed for the investigation of the tachykinins in
neonatal samples to be undertaken. The overall aim of the current clinical study was
to examine whether SP, NKA and Cortisol could be used as markers of persistent
pain in neonates.
Specific aims were:
i) To establish baseline concentrations of plasma and salivary SP and NKA in
normal healthy newborns and detect any variation between different
gestational age groups and postnatal ages.
ii) To investigate the relationship between plasma and salivary concentrations of
SP, NKA, and Cortisol.
iii) To observe how conditions which are likely to result in persistent pain,
e.g. meningitis, intraventricular haemorrhage (grades III and IV), necrotising
enterocolitis (NEC) and surgery, affect SP and NKA concentrations, and
whether analgesia makes a difference to the concentrations.
iv) To determine whether assisted ventilation is a cause of persistent pain or non-
painful stress to otherwise healthy but premature neonates. At the time of this
study, it was possible to capitalise on the Edinburgh Neonatal Unit's
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involvement in the international NEOPAIN study193, which was a randomised
double-blinded controlled trial investigating the routine use of morphine
infusions versus placebo to sedate ventilated preterm infants. SP and NKA
concentrations were assayed in these groups and compared between them as
well as with non-ventilated controls.
v) Comparison was made between Premature Infant Pain Profile (PIPP) scores
and physiological markers of pain and distress (heart rate and its variability)
in ventilated versus non-ventilated infants. I also examined any correlation
between these markers and SP or NKA concentrations.
The research hypothesis was that a rise in SP or NKA concentrations is a
manifestation of persistent pain in neonates.
5.2 Materials (See Appendix A)
5.3 Study design
5.3.1 Study cohort selection
The study was a prospective case-controlled observational cohort pilot study,
conducted at the Level III Neonatal Unit of the Simpson Memorial Maternity
Pavilion, at the Royal Infirmary of Edinburgh. The study period was from July 2000
to December 2001. There was no interventional group and hence no randomisation or
blinding was possible. Ethical approval was obtained from the Lothian Research
Ethics Committee (Ref: 1702/99/6/48) and the Lothian University Hospitals NHS
Trust Research and Development Office (Ref: 99/19/03). Infants were enrolled with
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written informed consent from parents, supported by an information sheet
(Appendix H). They were recruited in the first 24 hours of life. Inclusion criteria
were (i) normal healthy newborns of different gestational ages not requiring
ventilatory or other invasive support, (ii) newborns of any gestational age with a
'painful' condition, and (iii) newborns of any gestational age requiring ventilatory
support with no other apparent painful condition or intervention. Neonates who
developed NEC or meningitis or who underwent surgery were recruited within 24
hours of the illness developing. Exclusion criteria were chromosomal abnormalities,
periventricular leucomalacia and seizures.
The study cohort comprised 174 infants with a gestation range of 23 to 42 weeks.
Gestational scatter is shown in Graph 5.1. Table 5.1 shows the demographic
summary for the entire cohort, and Table 5.2 shows perinatal factors within different
gestational age groups.
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Table 5.1: Demographic summary for all study infants
Demographic factors N Mean ± 2SD Median (Range)
Gestation (weeks) 174 32.4 ± 9.7 32 (23 - 42)
Birth weight (grams) 174 1990.4 ± 2035.6 1845 (590-4610)
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Table 5.2: Perinatal factors within different gestational age groups
Gestational age group
< 28 weeks 29 - 32 weeks 33 - 36 weeks > 37 weeks
Number of infants 40 51 42 41
Median birth weight 822.5 1490 2055 3342
(grams) (Range) (590- 1320) (635 - 3000) (1324-2830) (1640-4610)
Caesarian section 45% 70.6% 66.7% 46.3%
Labour 80% 64.7% 54.8% 80.5%
Antenatal steroids 87.5% 91.7% 68.5% 2.4%
(N=48) (N=38)
Median Apgar at 1 min 5.5 1 8.5 9
(Range) (1-9) (2-9) (4-9) (3-9)
(N=38) (N=50)
Median Apgar at 5 min 8 9 9 9
(Range) (4-9) (4-9) (6-10) (5-9)
(N=38) (N=50)
Mean cord pH 7.25 7.26 7.27 7.27
(N=33) (N=38) (N=28) (N=20)
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5.3.1.1 NEOPAIN subgroup infants
Thirty-four infants < 32 weeks' gestation were concurrently enrolled into the
NEOPAIN study. All infants on a NEOPAIN study drug infusion (21 morphine,
13 placebo) were ventilated but had no other known painful condition. Gestation,
birth weight and perinatal factors were similar in both study drug groups (Table 5.3).
Statistics were performed using the unpaired t test for parametric data, and the Mann-
Whitney U test for non-parametric data.
Table 5.3: Demographic comparison of morphine and placebo groups of infants
enrolled in the NEOPAIN study
Demographic factors Morphine Placebo P value
N=21 N=13
Mean gestation (weeks) 27.3 26.6 0.4
Median birth weight (g) 1050 870 0.6
Median Apgar at 1 min 6 5 0.4
Median Apgar at 5 min 8 8 0.7
Mean cord pH 7.25 7.23 0.5
Caesarian section 11 (52%) 6 (42%) 1.0
Labour 17(81%) 11 (85%) 1.0
Antenatal steroids 17(81%) 12(92%) 0.6
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5.3.1.2 Infants with pain
Of 174 infants, 19 were believed to be suffering persistent pain, e.g. due to surgery,
NEC, severe intraventricular haemorrhage (IVH), meningitis (Table 5.4). For
simplicity, these infants will henceforth be referred to as being 'in pain'. Three infants
had both NEC and surgery. Five of these infants were enrolled from the surgical
Neonatal Unit at the Royal Flospital for Sick Children, Edinburgh. The gestational
scatter for infants in pain is shown in Graph 5.2. Nineteen controls matched for
gestation and ventilatory status were identified from the cohort. Table 5.5 shows the
demographic characteristics of the infants in pain and their controls.
Table 5.4: Conditions believed to be a source of persistent pain
Cause of pain Number of infants affected
Surgery (laparotomy or thoracotomy) 7
Chest drain 6
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Table 5.5: Characteristics of infants in pain versus controls
Infants in pain Controls
Gestation (weeks) 26-41 (median 33) 25-41 (median 33)
Birth weight (g) 640-3480 (mean 2000) 590-3770 (mean 2070)
Male:female 10:9 9:10
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5.3.2 Clinical sampling procedure
Once-daily, contemporaneous plasma and saliva samples were obtained on days 1, 2,
3, 7 and 14 from the study infants, with the exception of those in pain. They had up
to five daily samples taken during the course of their painful condition.
Sampling was opportunistic at a time when the infant required a clinically indicated
blood test. Prior to any handling, study infants were scored at rest using the
Premature Infant Pain Profile (PIPP) (See Section 1.4.1.4). A second PIPP score was
obtained during saliva suction as a standard intervention. If venepuncture was
required for the blood sample, then a third PIPP score was obtained to measure the
response to the pain stimulus. The Neonatal Unit at the Simpson Memorial Maternity
Pavilion has computer facilities for continuous trend monitoring of physiological
parameters such as heart rate (See Section 5.3.4). The time of study sampling was
recorded from the trend monitoring system. A 30 minute period of quiet rest prior to
the handling was later identified and heart rate data subsequently retrieved and used
for analysis of heart rate variability.
Saliva sampling was performed at least 30 minutes after the end of a feed to avoid
contamination of the saliva sample with mother's breast milk. This was important as
human milk is known to have high concentrations of SP (129.2 ± 27 ng/L)194. Saliva
was acquired by gentle suctioning of oral secretions at a pressure of 12 cmH20 in a
method identical to that routinely used to clear secretions in ventilated neonates. A
period of no more than 5 minutes was spent obtaining saliva, which was collected
directly onto freeze-dried aprotinin (50 pi) in a suction trap. The sample was then
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frozen immediately at -20°C. The Sarstedt Salivette® system was not used in the
infants as the Salivette rolls were too large, and there have been reports in the
literature of the device interfering with salivary hormone analyses, e.g. 17-
hydroxyprogesterone195.
Immediately after saliva collection, a blood sample was obtained from an indwelling
arterial line whenever possible, or a venepuncture concomitant with blood samples
required for clinical care. No additional venepunctures or heel lances were performed
solely for the purpose of the study. An extra 1 ml of blood was collected into a
polypropylene microtube containing freeze-dried aprotinin and EDTA (50 pi each).
The whole blood was mixed gently to avoid haemolysis and spun in a microfuge for
1 minute. Plasma was decanted into another identical microtube and frozen
immediately. The time taken for separation and freezing of plasma samples did not
exceed 10 minutes (Appendix G). Data were then recorded on the clinical state of the
infant and current treatment.
Reasons for not obtaining all data on all designated study days were:
• Infant discharged home or transferred to another hospital
• Infant deemed too clinically unstable for handling
• Clinically required blood samples already taken by clinical staff
• Heart rate monitoring not required
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5.3.3 Sample analysis
Plasma and saliva samples were stored at -70°C until analysis. Peptides were then
extracted using a solid phase extraction procedure and SP and NKA quantified using
in-house radioimmunoassays, developed as described in Chapter 3. Cortisol was
measured using a previously developed direct in-house immunoassay.
5.3.4 Heart rate data extraction and calculation of heart rate variability
Heart rate was recorded using either electrocardiograph (ECG) leads or by means of
continuous intra-arterial blood pressure waveform monitoring. The cotside system
used was the Siemens Infinity SC7000 modular monitoring series. Both ECG and
arterial heart rates were produced as analog output with < 25 ms delay.






Up to 12 leads
I, II, III, aVR, aVL, aVF, V, V+
15 - 300 /min
± 2 /min or ± 1% (whichever is greater)
Amplitude: 0.5 - 5.0 mV
Duration: 40 - 120 ms
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5.3.4.2 Intra-arterial bloodpressure waveform acquisition
Measuring method: Resistive strain gauge transducer
Display resolution: 1 mmHg
Measuring range: -50 to 400 mmHg
Accuracy: ± 1 mmHg or ± 3% exclusive of transducer (whichever is
greater)
Zero balance range: ± 200 mmHg
Transducer specifications: Siemens-approved transducers with a resistance of
200 - 300 Q and an equivalent pressure sensitivity of
5 pV/V/mmllg± 10%
5.3.4.3 The Badgerpatient data management system
Continuous trend data were recorded by the Badger System® (www.clevermed.com).
a real-time intensive care physiological monitoring and patient data management
system. The Badger System downloads and stores second-by-second readings of
physiological parameters produced by the Siemens monitoring system, including
heart rate, intra-arterial blood pressure, oxygen saturation, respiratory rate and
temperature (Figure 5.1). A 30 minute period of quiet rest prior to study handling
was identified for each infant. This period yielded 1800 second-by-second readings
of heart rate, which were extracted using a programme called BadgerView®. These
readings were then used for calculation of mean heart rate and heart rate variability.
Heart rate variability was computed as one standard deviation (1SD) of the mean
heart rate (See Section 1.4.2.1).
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Figure 5.1: Screenshot of the Badger System
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All data were analysed using SPSS for Windows Version 11.0. Data that were not
normally-distributed were tested using the Mann-Whitney U test. Normally-
distributed or log-transformed data were tested using an independent-samples t test.
Spearman correlation coefficients (r) are quoted with two-tailed tests of significance,
as the hormone data are not normally distributed. Pearson correlation coefficients
(also r) are used when data are of a normal distribution.
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6. CLINICAL STUDY: BASELINE CONCENTRATIONS OF PLASMA
SUBSTANCE P, NEUROKININ A AND CORTISOL IN NEONATES
AND FACTORS AFFECTING THEM
6.1 Introduction and aims
Before embarking on a study to investigate how SP and NKA may vary with pain in
neonates, it was important to establish baseline concentrations in neonates across
different gestational age groups, and to look for any natural variation in SP and NKA
concentrations with postnatal age or perinatal factors. These would be possible
confounding factors that would need to be taken into consideration when analysing
subsequent studies.
The specific aims here were:
i) To establish baseline concentrations of plasma and salivary SP and NKA in
normal healthy newborns and detect any variation between different
gestational age groups and postnatal ages.
ii) To investigate the relationship between plasma and salivary concentrations of
SP, NKA, and Cortisol.
iii) To see if perinatal factors affect SP and NKA concentrations in newborn
infants.
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The methods used are described in Chapter 5. Infants in pain were excluded from all
analyses for the description of baseline concentrations (Sections 6.1 to 6.3).
6.2 Baseline concentrations of plasma SP in neonates
Plasma SP concentrations in neonates ranged from 0.0 to 11.2 pmol/L (median 1.7
pmol/L). Fifty-five of 485 results yielded a result of 0.0 pmol/L (11%).
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6.2.1 Variation ofplasma SP with gestation
There was no significant correlation between plasma SP concentrations and gestation
(r = -0.12, P = 0.2) (Graph 6.1) and birth weight (r = -0.09, P = 0.3).
Graph 6.1: Variation of plasma SP with gestation
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Gestation (completed weeks)
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6.2.2 Variation of plasma SP with postnatal age
Postnatally, there was a gradual rise in median plasma SP during the first three days
which decreased again by day 14 (Graph 6.2). Using a one-way between subjects
analysis of variance (ANOVA), this postnatal variation of plasma SP was found to be
statistically significant (F(4, 480) = 5.189, P < 0.001). This pattern was more
apparent in preterm infants < 32 weeks' gestation (Graph 6.3) (ANOVA: F(4, 314) =
6.146, P< 0.001).
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= Extreme value (a value more than 3 box-lengths away from the box)
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6.2.3 Perinatal factors and plasma SP
On day 1, plasma SP showed no significant differences depending on mode of
delivery, presence of labour, use of antenatal steroids, maternal opiate administration,
maternal epidural administration, or maternal general anaesthetic administration
(Table 6.1). There was no correlation between plasma SP and cord pH (r = -0.07, P =
0.61).
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Table 6.1: The effect ofperinatal factors on plasma SP
P value
Mode of delivery SVD CS
N=31 N=39
Median plasma SP (pmol/L) 1.13 1.06 0.8
Presence of labour Labour No labour
N=48 N=22
Median plasma SP (pmol/L) 1.16 1.03 0.8
Use of antenatal steroids Yes No
N=56 N=14
Median plasma SP (pmol/L) 1.23 0.94 0.6
Maternal opiate administration Yes No
N=34 N=34
Median plasma SP (pmol/L) 1.47 0.87 0.09
Maternal epidural analgesia Yes No
N=31 N=37
Median plasma SP (pmol/L) 1.47 1.10 0.5
Maternal general anaesthesia Yes No
N=12 N=56
Median plasma SP (pmol/L) 1.04 1.14 0.6
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6.3 Baseline concentrations of plasma NKA in neonates
Plasma NKA concentrations in neonates were higher than plasma SP. They ranged
from 1.8 to 74.6 pmol/L (median 6.0 pmol/L).
6.3.1 Variation of plasma NKA with gestation
There was again no significant correlation between plasma NKA concentrations and
gestation (r = 0.06, P = 0.5) (Graph 6.4) or birth weight (r = 0.03, P = 0.7).
Graph 6.4: Variation of plasma NKA with gestation
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42
Gestation (completed weeks)
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6.3.2 Variation of plasma NKA with postnatal age
Postnatally, median plasma NKA showed a similar rise to SP over the first three days.
Subsequently, NKA concentrations decreased by day 7 whereas SP concentrations
did not decrease until day 14 (Graph 6.5). However, a one-way between subjects
ANOVA showed this variation not to be significant (F(4, 480) = 0.915, P = 0.6).
Although, as with SP, this pattern was more apparent in preterm infants < 32 weeks'
gestation (Graph 6.6), the ANOVA remained non-significant (F(4, 314) = 0.283, P =
0.9).
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Median NKA 6.15 6.20 6.46 5.42 4.72
(pmol/L)
N = 70 76 142 115 82
O = Outlier (a value more than 1.5 box-lengths away from the box)
a#
= Extreme value (a value more than 3 box-lengths away from the box)
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Graph 6.6: Variation of plasma NKA with postnatal age in preterm infants < 32
weeks' gestation
Postnatal Day
Median NKA 5.83 6.31 6.62 5.61 5.04
(pmol/L)
N = 54 55 77 74 59
O = Outlier (a value more than 1.5 box-lengths away from the box)
= Extreme value (a value more than 3 box-lengths away from the box)
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6.3.3 Perinatal factors and plasma NKA
Antenatal factors which have an influence on day 1 plasma NKA concentrations
were mode of delivery, the occurrence of active labour, and maternal epidural
analgesia (Table 6.2). Plasma NKA concentrations were significantly higher on day 1
in infants born by caesarian section than by spontaneous vertex delivery.
Concentrations were also significantly higher in the absence of labour. Maternal
epidural analgesia was associated with higher concentrations of plasma NKA. Other
perinatal factors did not have a significant effect on plasma NKA concentrations,
although maternal opiate administration approached statistical significance. There
was no correlation between plasma NKA and cord pH (r = -0.12, P = 0.39).
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Table 6.2: The effect of perinatal factors on plasma NKA
P value
Mode of delivery SVD CS
N=31 N=39
Median plasma NKA (pmol/L) 5.60 6.82 0.003
Presence of labour Labour No labour
N=48 N=22
Median plasma NKA (pmol/L) 5.82 6.93 0.005
Use of antenatal steroids Yes No
N=56 N-14
Median plasma NKA (pmol/L) 6.03 6.29 0.7
Maternal opiate administration Yes No
N=34 N=34
Median plasma NKA (pmol/L) 5.69 6.93 0.06
Maternal epidural analgesia Yes No
N=31 N=37
Median plasma NKA (pmol/L) 6.94 5.64 0.008
Maternal general anaesthesia Yes No
N=12 N=56
Median plasma NKA (pmol/L) 6.74 6.12 0.4
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6.4 Baseline concentrations of plasma Cortisol in neonates
Plasma Cortisol concentrations in this study ranged from 21.4 to 2842.5 nmol/L
(median 171.2 nmol/L).
6.4.1 Variation ofplasma Cortisol with gestation
Day 1 plasma Cortisol showed significant negative correlations with gestation
(r = -0.32, P < 0.001) (Graph 6.7) and birth weight (r = -0.26, P = 0.002)
(Graph 6.8).
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6.4.2 Variation of plasma Cortisol with postnatal age
Postnatally, plasma Cortisol concentrations on days 1 & 2 were higher than days 3, 7
and 14 (Graph 6.9). As the plasma Cortisol data were highly skewed, and the Levene
test for homogeneity-of-variance remained highly significant (P < 0.001) even with
logio plasma Cortisol values, a non-parametric test was used. The Kruskal-Wallis test
showed the postnatal variation to be non-significant (y2 (4) = 8.83, P = 0.065).
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O = Outlier (a value more than 1.5 box-lengths away from the box)
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= Extreme value (a value more than 3 box-lengths away from the box)
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6.4.3 Perinatal factors and plasma Cortisol
Antenatal factors which appeared to have an effect on day 1 plasma Cortisol
concentrations, but did not reach statistical significance, were mode of delivery and
labour (Table 6.3). There was a trend towards higher Cortisol concentrations with
spontaneous vertex deliveries rather than caesarian section, and with labour. There
was no significant effect of antenatal steroids on day 1 plasma Cortisol concentrations.
There was no correlation between plasma Cortisol and cord pH (r = 0.013, P = 0.92).
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Table 6.3: The effect of perinatal factors on plasma Cortisol
P value
Mode of delivery SVD CS
N=31 N=39
Median plasma Cortisol (nmol/L) 275.4 135.5 0.06
Presence of labour Labour No labour
N=48 N-22
Median plasma Cortisol (nmol/L) 251.0 131.5 0.06
Use of antenatal steroids Yes No
N=56 N=14
Median plasma Cortisol (nmol/L) 185.2 210.3 0.5
Maternal opiate administration Yes No
N=34 N=34
Median plasma Cortisol (nmol/L) 216.5 185.2 0.5
Maternal epidural analgesia Yes No
N—31 N=37
Median plasma Cortisol (nmol/L) 154.3 210.2 0.2
Maternal general anaesthesia Yes No
N=12 N=56
Median plasma Cortisol (nmol/L) 172.9 193.4 0.7
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6.5 Correlation between plasma hormones
There was some correlation between plasma SP and NKA, but no significant
correlation between either neuropeptide and plasma Cortisol (Table 6.4 and
Graph 6.10).
Table 6.4: Correlations between plasma hormones
N r P value
SP and NKA 551 0.13 0.003
SP and Cortisol 549 0.06 0.14
NKA and Cortisol 549 0.03 0.52
147
Chapter 6: Baseline concentrations ofplasma SP, NKA and Cortisol in neonates
Graph 6.10: Scatterplot of paired plasma NKA and plasma SP concentrations
Plasma Substance P (pmol/L)
6.6 Discussion
Of significant importance was that the plasma SP concentrations found in neonates in
this rigorously conducted study were lower than those published elsewhere. Scholle
et al reported mean (SE) plasma SP concentrations of 20.2 (4.6) pmol/L in 32
preterm infants, and 28.4 (5.7) pmol/L in 19 term infants190. However, the results in
Scholle's study were from unextracted plasma samples, which have been shown to
yield higher concentrations of SP due to cross-reactivity (Section 2.1). There was
also no description of sample handling and preservation procedures, which has been
shown to be of importance. Furthermore, despite claiming that their study was
'designed to determine the plasma concentration pattern of [SP] during the first year
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of life in full-term and preterm infants', Scholle et al only studied a small population
of infants, and the investigations were performed any time after the third week of life,
with results plotted according to the infants' corrected gestational age (which ranged
from -4 to 63 weeks (0 being term)). This gave rise to a very heterogeneous group of
infants, with a small number of infants having different numbers of plasma samples
contributing to the final results.
11% of the plasma SP results from the current study yielded a value of 0.0 pmol/L,
but these were probably genuinely undetectable concentrations as NKA remained
detectable in all the same samples, with concentrations ranging from 2.6 to 45.0
pmol/L (median 6.6 pmol/L). Moreover, other investigators have also reported
undetectable concentrations of plasma SP, not only in infants190, but also in
adults192'196'197. In addition, we now know that unextracted plasma gives higher
concentration measurements than extracted samples, and hence the accuracy of other
published reports on high plasma SP concentrations (300-500 pmol/L) where sample
extraction had not been performed138'198'199, is open to question.
Plasma NKA concentrations were found to be higher than those of plasma SP, and no
sample yielded an undetectable result. This is the first study of plasma NKA in
newborn infants, hence no comparisons are available. Most of the in vivo research
into NKA and pain has been in synovial fluid rather than plasma200"203.
When looking at day 1 samples from each infant, no correlation was found between
plasma neuropeptide concentrations, and gestation or birth weight (Sections 6.2.1
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and 6.3.1). However, day 1 samples can also be a reflection of perinatal
circumstances, hence the effect of various perinatal factors of the neuropeptides was
examined. Plasma SP concentrations were not affected by perinatal factors (Section
6.2.3) but unexpectedly, plasma NKA concentrations were higher in the absence of
labour, in infants born by caesarian section, and if maternal epidural analgesia was
administered (but not general anaesthesia) (Section 6.3.3). This was contrary to
expectation, as NKA concentrations would be predicted to rise with pain.
Nevertheless, although labour is painful to women, it is not known to cause pain to
the infant. Also, a normal delivery may be uncomfortable to the infant, but is not
known to be painful. It is recognised that labour induces endogenous P-endorphin
production in women204'205, as well as fetal P-endorphin levels as determined from
cord blood after delivery206'2 1. The fetal P-endophins may act as a natural analgesic
to the infant. Epidural analgesia, however, would reduce the pain of labour to the
mother. However, although epidural analgesia has been shown to attenuate maternal
P-endorphin production208, it does not affect fetal P-endorphin levels204'205. Maternal
opiate administration was associated with a trend towards lower neonatal plasma
NKA concentrations, which would be as anticipated.
With postnatal age, both plasma SP and NKA showed a gradual rise over the first
three days, followed by a subsequent decline, but was only statistically significant for
SP. This pattern was more marked in preterm infants less than 32 weeks' gestation.
Infants receiving intensive care are more likely to undergo multiple painful or
stressful procedures during the first days of initial stabilisation, which could explain
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this finding. Also, the more premature the infant, the more invasive procedures
required for stabilisation.
Plasma Cortisol concentrations in this study were similar to those found by Midgley
et al209, and fell with increasing gestation and postnatal age, again echoing findings
by other investigators209'210. There was no significant effect of antenatal steroids on
day 1 plasma Cortisol, a finding contrary to previous data obtained by some
researchers211. However, other investigators have found no effect of antenatal
steroids on cord Cortisol concentrations212. Also, the time between antenatal steroid
administration and delivery was not recorded in the current study, and this has been
shown to affect cord Cortisol concentrations21"1.
Finally, the current study shows that a weak correlation exists between plasma SP
and NKA, but not between either neuropeptide and Cortisol. The correlation between
the neuropeptides is unlikely to be due to cross-reactivity in the radioimmunoassays,
as this is <2%. It is more likely to be due to the fact that the same gene codes for
both neuropeptides (PPT-A gene, Section 1.5.2.1) and hence upregulation of the gene
for one peptide could result in increased production of the other peptide. NKA is co-
synthesised and co-secreted with SP, but has a different regional distribution and
asserts its effects via a different receptor to result in different biological functions.
The lack of correlation between the neuropeptides and Cortisol serves to reinforce the
theory that while Cortisol may be a good marker for non-painful stress, the
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neuropeptides may be better markers for pain. This hypothesis is explored in the next
chapter.
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7. CLINICAL STUDY: THE EFFECTS OF PERSISTENT PAIN AND
ASSISTED VENTILATION ON PLASMA SUBSTANCE P AND
NEUROKININ A IN NEONATES
7.1 Introduction and aims
Once the demographics of SP and NKA had been established in neonates, it was
possible to proceed with investigations into the effect of persistent pain and
ventilation on the concentrations of SP and NKA.
The specific aims here were:
i) To observe how conditions which are likely to result in persistent pain,
e.g. meningitis, intraventricular haemorrhage (grades III and IV), necrotising
enterocolitis (NEC) and surgery, affect SP and NKA concentrations, and
whether analgesia makes a difference.
ii) To determine whether assisted ventilation is a cause of persistent pain or non-
painful stress to otherwise healthy but premature neonates. At the time of this
study, it was possible to capitalise on the Edinburgh Neonatal Unit's
involvement in the international NEOPAIN study (Chapter 5).
iii) Comparison was made between Premature Infant Pain Profile (PIPP) scores
and physiological markers of pain and distress (heart rate and its variability)
in ventilated versus non-ventilated infants. Also, any correlation between
these markers and SP or NKA concentrations was investigated.
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The methods used are described in Chapter 5. Infants in pain were excluded from
analyses for variation with ventilation and analgesia (Sections 7.2 to 7.3).
7.2 Variation with persistent pain
As described in Section 5.3.1.2, 19 neonates were believed to be suffering persistent
pain. Area under the curve (AUC) was calculated for three consecutive daily
neuropeptide concentrations during the pain duration (Graph 7.1). Comparing the
pain group with their controls, there was no significant difference in median AUC for
either plasma SP (pain = 3.80, control = 3.03, P = 0.82) or plasma NKA (pain = 10.2,
control = 12.3, P = 0.33). Logio of plasma Cortisol values was computed and AUC
for the log values calculated. There was no significant difference in mean AUC for
log-transformed plasma Cortisol (pain = 4.68, control = 4.45, P = 0.25).
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Longitudinal graphs of plasma peptide concentrations over time were also examined
for individual infants and no consistent change noted with pain or analgesia
administration (Graphs 7.2a and 7.2b). Only 2 infants had plasma samples taken
before and after the painful event and the use of analgesia. The rest either did not
have samples taken before the onset of the painful event, or the infant was already on
analgesia by the time of enrolment.
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Graph 7.2a: Example of an individual infant's plasma neuropeptide concentrations
Plasma SP
-a— Plasma NKA
Onset of NEC, no analgesia Post-op da^s 1 to 4, on morphine
23456789 10 11
Postnatal Day
over time (Study subject 97)
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Graph 7.2b: Example of an individual infant's plasma neuropeptide concentrations
over time (Study subject 102)
Onset of NEC, no analgesia
0.0
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7.3 Variation with assisted ventilation
Median plasma neuropeptide values (pmol/L) and plasma Cortisol values (nmol/L)
are tabulated. Table 7.1 shows SP results from all neonates grouped by ventilation
and stratified by postnatal day. Tables 7.2 and 7.3 show NKA and Cortisol results in a
similar way. Tables 7.1a, 7.2a and 7.3a show the corresponding results for infants
< 32 weeks' gestation.
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Table 7.1: The effect of assisted ventilation on median plasma substance P
concentrations, stratified by postnatal day





1 39 1.10 31 1.47 0.7
2 40 1.63 36 1.34 0.6
3 46 2.03 96 2.00 0.2
7 30 1.89 85 1.75 0.4
14 20 1.51 62 1.33 0.5
Table 7.1a: The effect of assisted ventilation on median plasma substance P
concentrations, stratified by postnatal day (infants < 32 weeks' gestation only)
Postnatal Ventilated Not ventilated P value
day N SP N SP
(pmol/L) (pmol/L)
1 36 1.09 18 1.47 0.6
2 37 1.55 18 1.31 0.5
3 38 1.71 39 2.06 1.0
7 28 1.95 46 1.80 0.4
14 20 1.51 39 1.42 0.6
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Table 7.2: The effect of assisted ventilation on median plasma neurokinin A
concentrations, stratified by postnatal day





1 39 5.64 31 6.82 0.01
2 40 5.85 36 7.06 0.01
3 46 6.20 96 6.67 0.2
7 30 6.12 85 5.26 0.02
14 20 5.40 62 4.64 0.01
Table 7.2a: The effect of assisted ventilation on median plasma neurokinin A
concentrations, stratified by postnatal day (infants < 32 weeks' gestation only)





1 36 5.58 18 6.16 0.1
2 37 5.79 18 7.39 0.01
3 38 6.39 39 6.89 0.2
7 28 6.12 46 5.17 0.05
14 20 5.40 39 4.81 0.06
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Table 7.3: The effect of assisted ventilation on median plasma Cortisol
concentrations, stratified by postnatal day





1 39 319.8 31 85.4 < 0.001
2 40 325.7 35 128.1 < 0.001
3 46 209.1 96 139.5 < 0.001
7 30 260.0 84 167.1 0.001
14 20 211.6 62 125.9 0.002
Table 7.3a: The effect of assisted ventilation on median plasma Cortisol
concentrations, stratified by postnatal day (infants < 32 weeks' gestation only)
Postnatal Ventilated Not ventilated P value
day N Cortisol N Cortisol
(nmol/L) (nmol/L)
1 34 309.7 18 99.5 0.006
2 35 310.0 17 107.8 0.001
3 36 209.1 39 133.3 0.002
7 26 273.1 45 176.9 0.009
14 19 211.6 38 147.7 0.05
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Plasma SP concentrations were not found to be significantly different in ventilated
infants. Plasma NKA concentrations showed an unexpected variation, being
significantly lower in ventilated infants on days 1 & 2, and higher on days 7 & 14.
Plasma Cortisol concentrations were very significantly higher in ventilated infants
across all postnatal days, as would be expected of a marker of stress, whether painful
or not.
7.4 Variation with analgesia in ventilated infants (the NEOPAIN
subgroup)
In the subgroup of ventilated infants < 32 weeks' gestation who were also enrolled
into the NEOPAIN study, 21 received morphine therapy and 13 received placebo.
AUC was calculated as before for neuropeptide and logio Cortisol concentrations on
postnatal days 1 to 3 (Table 7.4). Comparing infants on morphine therapy with those
on placebo therapy, there were no significant differences in median AUC for plasma
SP or mean AUC for log-transformed plasma Cortisol. Median AUC for plasma NKA
was significantly lower in those ventilated infants who received morphine.
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Table 7.4: Median AUC for neuropeptide and logio Cortisol concentrations in
ventilated infants on postnatal days 1 to 3, morphine versus placebo groups
Median AUC P value
Morphine Placebo
N=19 N=12
Substance P (pmol/L) 3.21 3.38 0.5
Neurokinin A (pmol/L) 11.4 13.0 0.05
Logio Cortisol (nmol/L) 4.94 5.07 0.6
7.5 Correlation with PIPP scores and variation of PIPP scores with
assisted ventilation
Neither plasma SP nor NKA showed an appreciable correlation with either the
resting or suction PIPP scores, but plasma NKA showed a positive correlation with
PIPP scores from a pain stimulus (Table 7.5). Plasma Cortisol showed a negative
correlation with suction PIPP scores and pain stimulus PIPP scores. There was, as
expected, a positive correlation between resting and suction PIPP scores (r = 0.21,
P = 0.001), and suction and pain stimulus PIPP scores (r = 0.22, P = 0.01) (Graphs
7.3 and 7.4).
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Table 7.5: Correlations between hormones and PIPP scores
Resting P value Suction P value Pain P value
PIPP PIPP stimulus
score score PIPP score
r r r
SP 0.05 675 01)4 0.6 ~-O7O9 OT~
NKA 0.02 0.8 -0.08 0.2 0.32 <0.001
Cortisol 0.05 0.4 -0.22 <0.001 -0.24 0.01
Graph 7.3: Scatterplot of paired suction and resting PIPP scores
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It was noted that resting PIPP scores tended to be higher in infants receiving assisted
ventilation than non-ventilated infants (Table 7.6). Although the difference in scores
between ventilated and non-ventilated infants was statistically significant on
postnatal days 1 and 2, the actual difference of 1 point in the score was clinically
insignificant. With PIPP scores in response to suction, the reverse was found, though
not statistically significant (Table 7.7). Unfortunately the number of ventilated
infants who had a PIPP score performed with a painful stimulus was very small, as
most of these infants had arterial lines from which blood was sampled, thereby
avoiding venepuncture (Table 7.8).
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Table 7.6: The effect of assisted ventilation on median resting PIPP scores, stratified
by postnatal day
Postnatal Ventilated Not ventilated P value
day N Median N Median
resting resting
PIPP score PIPP score
1 35 5 27 4 0.02
2 32 5 24 4 0.003
3 28 6 22 4.5 0.07
7 20 5 20 5 0.9
14 12 6 14 5 0.6
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Table 7.7: The effect of assisted ventilation on median suction PIPP scores, stratified
by postnatal day
Postnatal Ventilated Not ventilated P value
day N Median N Median
suction suction
PIPP score PIPP score
1 35 11 27 13 0.3
2 32 10 24 12 0.2
3 28 11 22 13.5 0.3
7 20 11 20 12.5 0.4
14 12 11.5 14 12 0.7
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Table 7.8: The effect of assisted ventilation on median pain stimulus PIPP scores,
stratified by postnatal day
Postnatal Ventilated Not ventilated P value
day N Median N Median
pain PIPP pain PIPP
score score
1 2 15.5 17 15 0.6
2 2 10.5 19 15 0.2
3 3 10 19 12 0.08
7 6 11.5 19 11 0.6
14 11 14 11 10 0.3
Correlation with heart rate and heart rate variability,
variation of heart rate data with assisted ventilation
Plasma SP and NKA showed no correlation with either mean heart rate or heart rate
variability (Table 7.9). Plasma Cortisol, however, correlated positively with mean
heart rate and negatively with heart rate variability (Graphs 7.5 and 7.6).
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Table 7.9: Correlations between hormones and heart rate data
Mean heart P value Heart rate P value
rate variability
SP 0.12 0.06 -0.04 0.5
NKA -0.03 0.7 -0.06 0.4
Cortisol 0.23 < 0.001 -0.19 0.004
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Surprisingly, assisted ventilation had little effect on mean heart rate. Mean heart rate
was generally higher in ventilated infants, but this was only statistically significant
on postnatal day 1 (Table 7.10). However, heart rate variability was a more useful
marker of stress, as it was reduced as expected in ventilated infants, being
statistically significant on postnatal days 1, 2 and 7 (Table 7.11).
Paradoxical results were obtained when AUC comparisons were made between
ventilated infants who were randomised to morphine or placebo in the NEOPAIN
subgroup (Table 7.12). It was anticipated that morphine would result in a reduction
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in mean heart rate and an increase in heart rate variability, but a trend (not
statistically significant) was observed in the opposite direction.









1 35 148.2 21 143.3 0.02
2 33 155.9 18 148.1 0.06
3 32 156 18 150.4 0.1
7 18 160.1 19 157.7 0.9
14 11 160.1 12 160.4 0.8
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Table 7.11: The effect of assisted ventilation on heart rate variability, stratified by
postnatal day
Postnatal Ventilated Not ventilated P value
day N Median N Median
HRV HRV
_ _ _
2.9 21 53 0.003
2 33 4.5 18 7.0 0.007
3 32 4.3 18 5.2 0.1
7 18 4.8 19 6.7 0.04
14 11 5.0 12 6.3 0.8
Table 7.12: Median AUC for heart rate data in ventilated infants on postnatal days 1
to 3, morphine versus placebo groups
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7.7 Longitudinal analysis of changes in tachykinin and Cortisol
concentrations with analgesia
All data were examined for instances where successive tachykinin concentration
results were available over time period where there was a change in the pain status of
the infant. There were only in 2 instances in which tachykinin concentrations had
been taken before and after an infant developed a painful condition (Section 7.2).
However, there were 12 occasions in which plasma concentrations were measured
before and after starting analgesia, whether it was for ventilation or for pain.
These changes are demonstrated in Graphs 7.7, 7.8 and 7.9. The mean percentage
changes for neurokinin A and Cortisol were +1.1% and -0.9% respectively,
indicating that the changes occurred in either direction with analgesia. With
substance P, the percentage change could not be calculated for 4 of the infants as
they had substance P concentrations of 0.0 pmol/L. For the remaining 8 infants, the
percentage change was +3.4%.
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Graph 7.7: Change in plasma substance P concentrations with the administration of
analgesia in 12 infants
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Graph 7.8: Change in plasma neurokinin A concentrations with the administration
of analgesia in 12 infants
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Graph 7.9: Change in plasma Cortisol concentrations with the administration of
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7.8 Discussion
To determine whether SP and NKA concentrations varied with pain, a case-control
study was set up and 19 infants thought to be in persistent pain were enrolled. There
were no differences in plasma SP, NKA or Cortisol concentrations between the pain
group and their controls (Section 7.2). One major limitation of this observational
study was that 15 of 19 infants believed to be suffering pain had already received
analgesia prior to study enrolment, and it was possible that they were no longer in
176
Chapter 7: The effects ofpersistent pain and assisted ventilation on plasma SP andNKA in neonates
pain. However, it is arguable on ethical grounds that the treatment of pain should not
be withheld for any study. Analysis of the 4 who had not received prior analgesia
yielded no significant differences in SP or NKA concentrations compared with either
those who had received analgesia, or the controls.
Examination of plasma peptide concentrations over time for each infant within the
'pain' group also showed no consistent change with pain or analgesia administration
(Section 7.2). However, in the whole cohort, there were 12 instances where infants
had plasma samples taken before and after starting analgesia, whether for ventilation
or for pain (Section 7.7). The percentage change was calculated for each of these
occasions, but the mean percentage change was close to nil for each of the
tachykinins, indicating that one could expect a change in plasma concentrations in
either direction following the administration of analgesia. This longitudinal
examination is limited by the fact that only 12 infants could be studied in this way.
Plasma Cortisol was significantly higher in ventilated infants compared with non-
ventilated infants, across different postnatal age groups (Table 7.3). Stratification
across postnatal age was performed as plasma SP, NKA and Cortisol concentrations
were found to vary with postnatal age (Section 6.6). It is accepted that there are
fundamental differences in the physiology of infants requiring ventilation versus
those not requiring it. Infants who are more ill, e.g. with sepsis, are also more likely
to need ventilatory support, and may have higher plasma Cortisol concentrations as a
non-painful stress response to their sepsis rather than as a pain response.
Randomisation of newborn infants to ventilation or not is therefore not possible. For
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example, an infant is more likely to require ventilation if it is more premature, and
Cortisol is higher in more premature infants (Section 6.4.1). Subanalysis of infants
within gestational groups is difficult however, e.g. of 27 infants born < 28 weeks'
gestation, all but one were ventilated on days 1 and 2 of life in the current study. On
day 3, 30 of 35 infants < 28 weeks' gestation continued to require ventilatory support.
To eliminate the confounding factor of gestational age, the results were also analysed
only for those infants < 32 weeks' gestation (Table 7.3a). Despite there being smaller
numbers, the differences between plasma Cortisol concentrations of ventilated and
non-ventilated infants remained highly significant.
Plasma SP concentrations yielded unexpected results, being not significantly
different in ventilated infants (Tables 7.1 and 7.1a). As the original research
hypothesis was that a rise in SP concentration was a manifestation of persistent pain
in neonates, this finding leads to two possible deductions. Firstly, that production of
SP in neonates is not upregulated in persistent pain, or secondly, that ventilation does
not cause persistent pain to newborn infants. In fact, the question of whether plasma
SP actually increases in painful conditions in adults (Section 1.5.1.4) has been raised
again, now that sample extraction has been shown to be important for accurate
determination of plasma concentrations (Chapter 2). Onuoha et al published three
papers reporting raised plasma concentrations in adults with soft tissue injury198,
fractured necks of femur214 and early burns215, but did not use any form of plasma
extraction. Marshall et al also reported increased plasma SP concentrations in adults
with arthritis, but did not use plasma extraction either1,8. Finally, Molina also
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published raised plasma SP concentrations in cases of spinal arachnoiditis, but did
not provide any information on plasma extraction, sample handling, or assay type199.
Conversely, those investigators who performed plasma extraction found no increase
in SP in either acute pain (labour and post-operative136), or persistent pain (chronic
headache196, fibromyalgia216, arthritis192, chronic low back pain137). Hence it is
feasible that plasma SP does not actually rise in response to persistent pain in either
adults or neonates, although this does not negate the possibility that local
upregulation in the central nervous system may occur.
Plasma NKA concentrations showed unexpected variation with ventilation, being
significantly lower in ventilated infants on days 1 and 2, and higher on days 7 and 14
(Table 7.2). Even in the smaller subgroup of infants < 32 weeks' gestation, this
pattern was still significant on days 2 and 7, with a trend towards being significant on
day 14 (Table 7.2a). Again, if one assumes the hypothesis that a rise in NKA
concentration is a manifestation of persistent pain in neonates, the results on days 7
and 14 would be in keeping with the theory of assisted ventilation being a source of
persistent pain. The next step to determining if this were true, would be to see if the
administration of analgesia modifies the NKA response (Section 7.3). This was
performed in the context of a randomised double-blinded placebo-controlled trial
(NEOPAIN, Section 5.3.1.1). Administration of analgesia in the form of a
continuous intravenous infusion ofmorphine resulted in a significantly lower plasma
NKA concentrations, indicating that analgesia did indeed modify the NKA response.
On the other hand, analgesia appeared to have no effect on plasma SP or Cortisol
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concentrations. This is probably because plasma SP was already shown not to rise in
response to assisted ventilation in neonates, and whilst plasma Cortisol may be a
good marker for non-painful stress, it may be a less specific marker for persistent
pain.
The unexpected results of plasma NKA concentrations being significantly lower in
ventilated infants on days 1 and 2 may be related to the effect of perinatal factors
(Section 6.6). Ventilated infants were more likely to have undergone labour, been
born by spontaneous vertex delivery, and their mothers not have epidural analgesia,
all factors which were associated with lower plasma NKA concentrations on day 1,
although the only statistically significant difference was with regard to labour (Table
Table 7.13: Differences in perinatal factors between ventilated and non-ventilated
infants
7.13).
Antenatal factors Ventilated Not ventilated P value
N (%) N (%)
Labour 32/39 (82%) 16/31(52%) 0.01
SVD 21/39 (54%) 10/31(32%) 0.07
No epidural analgesia 24/39(62%) 13/31(42%) 0.07
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The PIPP multimodal infant pain assessment tool was used to obtain a measurement
of the degree of pain the infants may have been in using behavioural and
physiological indicators (Section 1.4.1.4). The difficulty with using PIPP scoring is
that it has been validated for acute procedural pain such as venepuncture, but not for
persistent pain. Resting scores have only recently been investigated and validated for
post-operative pain assessment49. Scores in response to oral suction have not been
validated before. However, as most of the ventilated infants had blood samples taken
via an indwelling arterial line, pain stimulus scores would not be available for this
important group of infants, hence suction scores were measured as oral suction was a
standard intervention undergone by all infants for the collection of saliva.
There was no difference between ventilated and non-ventilated infants with regard to
their suction and pain stimulus PIPP scores. Resting PIPP scores showed a
statistically significant difference between ventilated and non-ventilated infants on
postnatal days 1 and 2, but the actual difference of 1 point in the score was clinically
insignificant (Table 7.6). Suction PIPP scores were generally higher in non-
ventilated infants, though not statistically significant (Table 7.7). This could be due
to the fact that PIPP scores include assessment of a facial grimace, which may be less
visible in an infant with an endotracheal tube in-situ. However, a lack of facial
grimace could also be an indication of persistent pain. Unfortunately the number of
ventilated infants who had a PIPP score performed with a painful stimulus was very
small, making interpretation of those results very difficult (Table 7.8).
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Plasma SP showed no correlation with PIPP scores, though this is unsurprising as SP
was shown not to rise in response to assisted ventilation (Table 7.5). Plasma NKA
showed a strongly significant positive correlation only with pain stimulus PIPP
scores, despite there being fewer infants with pain stimulus PIPP scores than resting
or suction scores. This may indicate that the infants who reacted most strongly to
procedural pain already had some upregulation of their background pain mechanisms.
Plasma Cortisol showed a significant negative correlation with suction and pain
stimulus PIPP scores, which may be because sicker infants who are under more
physiological stress are more likely to exhibit frozen facial appearance and
behaviour42.
Heart rate and its variability were also used as other proxy measures of pain. Figure
7.1 shows Badger System® screenshots comparing normal and reduced heart rate
variability graphical trend displays.
Figure 7.1: Badger System® screenshots comparing normal (top) and reduced
(bottom) heart rate variability graphical trend displays
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Although mean heart rate was generally higher in ventilated infants, this was only
statistically significant on postnatal day 1 (Table 7.10). However, a reduced heart
rate variability appeared to be more reflective of the degree of stress experienced by
ventilated infants (Table 7.11). Reduced heart rate variability has already been shown
to be indicative of neonatal sepsis and systemic inflammation217, and to be associated
with neonatal mortality218. It is also seen antenatally on cardiotocograms as an
9 1Q-990
indication of fetal stress in utero ' " . In adults, reduced heart rate variability after
myocardial infarction is prognostic of reduced long-term survival221. It is therefore
unsurprising that plasma Cortisol, an established marker of stress, shows a strongly
significant positive correlation with mean heart rate, and negative correlation with
heart rate variability (Table 7.9). Disappointingly, neither plasma SP nor NKA
showed any correlation with heart rate or its variability.
It is more difficult trying to delineate whether the reduced heart rate variability in
ventilated infants is due to the stress of pain, or of being sicker and consequently
needing ventilatory support. If the heart rate variability was reduced because of pain,
then administration of analgesia to ventilated infants should reverse the phenomenon
of decreased variability. However, this is not the case (Table 7.12). Heart rate
variability was not modulated by analgesia, as was found to be the case for plasma
Cortisol. Both plasma Cortisol and heart rate variability therefore appear to be good
markers for non-painful stress, but not for persistent pain.
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8. CLINICAL STUDY: SALIVA SUBSTANCE P AND NEUROKININ A
IN NEONATES
8.1 Introduction
The aim of investigating SP and NKA in saliva samples was to find a less invasive
alternative to blood sampling. This would require SP and NKA concentrations to be
mirrored between plasma and saliva samples.
296 saliva results were obtained, compared with 485 plasma results. The remaining
189 samples were either insufficient (ie. empty) or missing. Saliva samples were
completely missing from (i) all five infants enrolled from the Royal Hospital for Sick
Children, Edinburgh, (ii) subjects no. 70 to 97, and (iii) subjects no. 127 to 136.
Consequently, only 131 of the cohort of 174 infants had saliva results, and of these
131, 107 infants had incomplete results due to insufficient or missing samples on
various days.
Of the 296 saliva samples analysed, 161 (54%) were < 50 pi, 64 (22%) were < 20 pi,
and 42 (14%) were < 10 pi. This was due to low saliva yields in the infants. By
comparison, only 8 of 485 plasma samples were < 50 pi (0.02%). Furthermore, a
poor NKA standard curve was encountered during radioimmunoassay analysis of
samples from subjects no. 144 to 170. A total of 93 NKA results were therefore
rendered unreliable. However, this still left 203 saliva NKA results for interpretation.
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In view of the multiple difficulties encountered with saliva sampling, and the
consequent poor and patchy yield in results, only limited statistical data analysis was
performed.
8.2 Correlation between saliva hormones, and with plasma equivalents
There was statistical correlation between saliva SP and saliva NKA (r = 0.20,
P = 0.005). However, inspection of the actual scatterplot for these results showed that
there was no clinically useful relationship between the two salivary hormones (Graph
8.1). A considerable number of samples yielded high concentrations ofNKA with no
detectable concentrations of SP, and vice versa. Saliva SP correlated weakly with
plasma SP (r = 0.14, P = 0.016) (Graph 8.2) but saliva NKA did not correlate at all
with plasma NKA (r = 0.02, P = 0.8) (Graph 8.3).
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8.3 Baseline concentrations of saliva SP in neonates
As with plasma SP, there was an overall skewed distribution of saliva SP
concentrations. For infants not in pain, these ranged from 0.0 to 115.16 pmol/L, an
appreciably larger range than for plasma SP concentrations. However, 198 samples
yielded a result of 0.0 pmol/L (67%), and the median saliva SP concentration was
therefore 0.0 pmol/L. The large number of samples yielding this result could be due
to sample volumes being small. Furthermore, only 18 results were > 15 pmol/L, and
of these, 16 were from sample volumes that were 50 pi or less, illustrating that small
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sample volumes can also lead to large errors due to the multiplication factors
involved after sample extraction.
Saliva SP also showed a weak statistical correlation with gestation (r = 0.25, P = 0.02)
and birth weight (r = 0.22, P = 0.04), but again, the scatterplots revealed no important
association.
8.4 Baseline concentrations of salivaNKA in neonates
Saliva NKA also demonstrated an overall skewed distribution. For infants not in pain,
concentrations ranged from 0.0 to 942.04 pmol/L, again a much larger range than for
plasma NKA. Unlike plasma NKA, which was always detectable, 102 saliva samples
yielded an NKA result of 0.0 pmol/L (50%), making the median saliva NKA
concentration also 0.0 pmol/L. Again, only 9 results were > 200 pmol/L, and 7 of
these were 10 pi samples.
Saliva NKA showed no correlation with gestation (r = 0.22, P = 0.07) or birth weight
(r = 0.19, P-0.12).
8.5 Discussion
Saliva sampling proved challenging in newborn infants. It was often noted that saliva
production was scanty, and this was reflected by the poor yield in results. It is also
difficult to distinguish gingival crevicular fluid and mucus from saliva in neonates. In
fact, it is probably more accurate to call it oral fluid sampling, rather than saliva
sampling. Furthermore, copious amounts of oral fluid were obtained from babies
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who were paralysed with pancuronium or vecuronium, which could cause potential
bias in results.
A number of methodological problems must be acknowledged here. Despite
intensive efforts to trace them, all saliva samples from 43 infants went missing from
the laboratory. This included samples from 13 of the 19 infants thought to have been
in pain. It was also disappointing that a poor NKA standard curve rendered 93 saliva
NKA results unreliable.
The high number of missing or insufficient results meant that most infants had
incomplete data, hence variation of saliva SP and NKA with postnatal age could not
be investigated. Correlation between the saliva neuropeptides, and with their plasma
equivalents, could be performed, but this only showed a weak relationship between
saliva and plasma SP (Section 8.1).
Although saliva SP concentrations appeared to be detectable at a higher range than
plasma SP (up to 115.16 pmol/L versus 11.2 pmol/L), the median saliva SP
concentration was in fact 0.0 pmol/L, compared with 1.7 pmol/L in plasma (Section
8.2). This is because 198 (67%) of 296 saliva samples yielded a result of 0.0 pmol/L
for SP. The high concentrations were from sample volumes that were very small, and
probably resulted from the large multiplication factors required after sample
extraction. Overall, therefore, saliva SP existed in lower concentrations than plasma
137SP in neonates, which is contrary to findings in adults .
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The same was true for saliva NKA concentrations. Although the range of NKA
concentrations extended to 942.04 pmol/L in saliva, versus a maximum of 74.6
pmol/L in plasma, the median saliva NKA concentration was also 0.0 pmol/L. This is
compared with a median plasma NKA concentration of 6.0 pmol/L.
It is possible that a large number of saliva SP and NKA results yielded a value of 0.0
pmol/L because there was not sufficient saliva in the oral fluid collected. It could
also be that SP and NKA exist in saliva in concentrations below the limit of detection
of the radioimmunoassays. Another conclusion might be that the salivary glands of
the neonate do not produce SP and NKA in significant quantities, even under
circumstances which might be considered painful or stressful. Further work requires
to be done to test this hypothesis.
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9. SUMMARY AND CONCLUSIONS
In neonatal intensive care, it is a daily challenge to ascertain whether infants
requiring ventilatory support are experiencing pain, and if so, to determine how
much pain they are in and whether it is alleviated by analgesia. Infants are preverbal
and hence cannot describe their discomfort. The sickest and most premature infants
are also the ones least able to communicate their pain and distress. Yet, there is
evidence that infants can feel pain, and that they are able to mount an endocrine and
metabolic stress response to it. This response can be detrimental to the infant, by
promoting a catabolic state, water retention, hyperglycaemia, and impairing bowel
and immune function. Wound healing is impaired and susceptibility to infection is
increased, together with mortality.
The ability to measure pain in infants undergoing neonatal intensive care, as well as
to monitor responses to analgesia, would facilitate more efficient pain management.
Behavioural measures are the mainstay of infant pain assessment, but these have
principally been devised for assessing acute rather than persistent pain. Such
techniques also cannot be used when an infant is paralysed, which is sometimes
necessary in the sickest infants. Physiological measures, such as heart rate, are
affected by many other factors, e.g. infection, drugs, and simple handling. Many
existing neurochemical measures are markers for non-painful stress rather than pain.
This series of studies has served to confirm this for both plasma Cortisol and heart
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rate variability (Sections 7.4 and 7.6). There is therefore the ongoing need to find a
suitable marker for pain that could eventually be developed for clinical use. There is
currently no gold standard measure for persistent pain in newborn infants, but that
should not preclude the study into possible future markers of pain.
Worldwide, these are the first studies of SP and NKA in newborn infants. Plasma SP
and NKA concentrations in newborn infants are described across various gestational
ages and changes with postnatal age are investigated. It is also the first to examine
whether concentrations of SP or NKA are affected by persistent pain, assisted
ventilation, or the administration of analgesia.
To conduct this study with rigour, methods of sample handling and laboratory
analysis to maintain neuropeptide stability and to ensure result validity were
scrutinised (Chapters 3 and 4). A significant number of previous publications on in
vivo studies of SP have reported that concentrations of SP vary with different clinical
conditions, but where these have failed to employ the use of sample extraction, their
findings have now been thrown into doubt. Even existing radioimmunoassay kits for
analysing adult plasma samples have quoted extraction procedures that are
suboptimal, resulting in little or no recovery of the relevant neuropeptide.
Peptide extraction was found to be essential for the accurate analysis of plasma SP
and NKA (Chapter 2). Both liquid phase and solid phase extraction procedures have
been evaluated in the current studies. Different solid phase extraction columns and
mobile phases were also tested. It was important that a single extraction procedure
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yielded high recoveries for both neuropeptides, as both SP and NKA concentrations
needed to be measured in each sample.
Apart from sample extraction, the radioimmunoassays for both neuropeptides also
needed to be modified for analysis of neonatal microsamples (Chapter 3). The most
specific antibody was chosen, then ideal antibody concentrations determined. The
stability of standards was checked. Disequilibration of the assays and different
second antibodies made little difference to the assay.
Plasma SP concentrations found in this study (median 1.7 pmol/L) were similar to
those found in other adult studies that employed sample extraction prior to assay
(Section 6.2). For example, Joyce et at91 used enzyme inhibitors, a validated
extraction procedure, HPLC coupled with RIA, and found that SP concentrations in
plasma and synovial fluids in patients with arthritis were approximately 1000-fold
less than those previously reported by others using less stringent analytical
techniques, e.g. Marshall et a/138. As in this study, Joyce found that unextracted
plasma and synovial fluid gave higher measurements than extracted samples. The
only other study on plasma SP in infants was in babies over the age of three weeks,
and no sample extraction was performed190. It is therefore likely that these results are
a more accurate reflection of true plasma SP concentrations in newborn infants.
Plasma SP concentrations were found to be very low, and often undetectable, despite
the use of a rigorous extraction technique and a modified assay for increased
sensitivity (Section 6.2). Plasma NKA concentrations existed in higher amounts than
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plasma SP (median 6.0 pmol/L) (Section 6.3). This may not be surprising as there is
evidence from neurobiological studies that SP exerts its effects locally at the site of
stimulation of primary afferents, whilst NKA activates more distant sites117. SP may
therefore tend to be a more useful marker of upregulation in nociceptor activity if
measured locally, e.g. in synovial fluid in arthritis, or in the CSF in headaches and
other painful spinal diseases. It is maybe therefore unsurprising that different
researchers found conflicting results when studying the changes in plasma SP with
chronic pain of various origins (Section 1.5.1.4). Also, it would be even less likely
for changes in salivary SP to be perceived if plasma SP already shows such a low
level of detection and little measurable change. NKA is more likely to be detected
systemically if it exerts its effects at more distant sites.
The current studies show that gestation and birth weight have no effect on plasma SP
or NKA (Chapter 6). Plasma SP and NKA show changes with postnatal age, more
marked in preterm infants. The slight increase in the first three postnatal days and
subsequent fall back to baseline seems in line with other pain/stress regulators, e.g.
catecholamines. In early postnatal days, multiple factors may influence SP and NKA
concentrations, including perinatal circumstances. This is seen in unexpectedly
higher plasma NKA concentrations in the absence of labour, in infants born by
caesarean section, and if maternal epidural analgesia was administered. The
mechanisms behind this apparent upregulation of NKA are unclear, and further
research on NKA concentrations in umbilical cord blood samples may shed light on
this, as they would help differentiate changes in concentrations due to postnatal
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events versus perinatal factors. Perinatal factors did not appear to affect plasma SP
concentrations.
In these studies, persistent pain did not appear to have a significant effect on
concentrations of either neuropeptide (Section 7.2). It is possible that some or all of
the infants were not in persistent pain as was assumed. However, it may also be due
to adequate treatment of pain with analgesia administration. Only 4 of the 19 infants
in pain did not receive analgesia. Then again, the appropriate treatment of pain
should not be withheld for any study. It was more feasible to study SP and NKA
concentrations in a population of infants who were not routinely receiving analgesia,
but exposed to another source of possible pain or distress, such as assisted ventilation.
This was investigated opportunistically with infants involved in the NEOPAIN study
(Section 7.4).
The results of the NEOPAIN study have now been published193. A total of 898
ventilated infants were enrolled from 16 centres with equal division into morphine
and placebo arms of the trial. Pre-emptive morphine infusions did not reduce the
frequency of severe IVH, PVL, or death in ventilated preterm neonates, but
intermittent boluses of open-label morphine were associated with an increased rate of
the composite outcome. The morphine doses used in the study decreased clinical
signs of pain but also caused significant adverse effects in ventilated preterm
neonates.
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Prolonged opiate administration may also produce unwanted pro-nociceptive
adaptations which result in hyperalgesia222. SP and NK1R expression is also
increased in the spinal dorsal horn during sustained opiate therapy. Hence the use of
prolonged opiate infusions in the NEOPAIN study may have resulted in an
upregulation of SP concentrations and therefore a false negative in finding a
decreased concentration with analgesic therapy.
With regard to either pain or assisted ventilation, plasma SP concentrations did not
appear to be a useful marker of persistent pain or distress. Conversely, plasma NKA
concentrations did not vary with pain, but showed significant changes with
ventilation, which were further modulated by the use of analgesia. This was seen on
the cross-sectional analysis of results (Section 7.4). However, in a small subgroup of
infants, there was the opportunity to study data longitudinally (Section 7.7). In this
subgroup, the mean percentage change in plasma neuropeptide concentrations was
close to nil, indicating that changes could occur in either direction with the
administration of analgesia. However, this was studied in only 12 infants, hence the
cross-sectional data comparing 31 infants may be more representative.
In the cross-sectional analyses, Cortisol responses in the same group of infants
demonstrated significant changes with ventilation, but not with analgesia. This
suggested that although Cortisol is a useful indicator of overall non-painful stress,
NKA might be more specific for pain.
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The current studies found a weak correlation between plasma SP and NKA (Section
6.5). Given that SP and NKA are generally co-synthesised and co-secreted when the
PPT-A gene is switched on, a correlation is not unexpected. That it is a weak one,
however, probably confirms again that the two peptides are different in their
biological functions, activity and areas of action (Sections 1.5.1.3 and 1.5.2.2).
Plasma SP did not correlate with plasma Cortisol or other physiological measures of
pain used in this study (Sections 6.5, 7.5 and 7.6). Plasma NKA did not correlate
with plasma Cortisol, but showed some correlation with pain stimulus PIPP scores
only. This could be due to a true lack of change in plasma SP and NKA with pain,
but could also be due to the physiological and behavioural measures themselves
being inadequate measures of persistent pain. As mentioned in Section 1.4.1.4, PIPP
scores have been validated mainly for use with acute pain, while the infants in this
study were exposed to more persistent pain. Yet the PIPP score was chosen as the
best possible behavioural measure of persistent pain because it is the only measure
which has been validated for use in more persistent pain, i.e. post-operative pain. The
results from these studies give some indication that the PIPP may still not be an
adequate score for the assessment of chronic pain. There is therefore still a need for
better clinical assessment of chronic pain in infants.
Heart rate variability was found to be a better marker of stress in ventilated infants
than PIPP scoring (Section 7.6). PIPP scoring in a premature infant, although
predominantly a behavioural marker with a more 'emotional' component than a
chemical marker, is nevertheless still likely to be more a measurement of nociceptive
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circuit reflex behaviour rather than a true emotional pain response. Neither
neuropeptide correlated with heart rate variability, whereas plasma Cortisol did. As
with plasma Cortisol, heart rate variability was not modulated by the use of analgesia,
suggesting that both were markers for non-painful stress but not necessarily for pain.
There is therefore still no gold standard measure for the assessment of chronic or
persistent pain in newborn infants, especially premature ones. Chronic pain which is
of sufficient importance would be that which leads to physiological or psychological
maladaptation, or neurobiological 'rewiring' and subsequent hyperalgesia, allodynia
or dysaesthesia. Perhaps the only way of determining which infants suffer this would
be to assess their pain responses on long-term follow-up, perhaps even into
adulthood if necessary.
Understanding the neurobiology of pain transmission in premature infants also
makes us realise that it is not only painful stimuli that need treating, but also other
tactile stimuli (Section 1.1.4). Receptive fields in neonates are larger and more
disorganised, and in premature infants hyperstimulation with a lack of local
regulation may have noxious consequences. Neurotrophin concentrations themselves
are partly responsible for nociceptor innervation density in the skin and can be
upregulated by neonatal skin wounding5. Unfortunately, premature infants are
subject to multiple skin wounds during the course of their intensive care, and this can
result in local upregulation of neurotrophins in the skin, possibly also detected in
plasma samples. With adequate treatment of these repeated skin wounds, the
nociceptor innervation density may possibly be normalised, although the evidence
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for this from animal studies is still awaited. We now know it is important to treat
neonatal pain to avoid subsequent abnormal pain reception or behaviour14.
So, where to from here? Will there ever be a reliable behavioural, let alone
neurochemical, measure of pain in newborn infants to be found? Even if a
neurochemical marker is discovered, it is more likely to be measure of nociceptor
pathway upregulation rather than pain. However, if it proves to be a reliable measure
of persistent pain, development of a bedside assay would allow it to be used in
clinical care.
In this pilot study, the findings with regard to NKA suggest further investigation is
warranted. SP appears to be detected in plasma at concentrations too low to ascertain
any variation, and perhaps should be measured at a local rather than systemic level.
The unexpected variations of NKA with labour, caesarean section, and maternal
epidural analgesia may best be examined by comparing cord blood samples of
neuropeptide concentrations with day 1 samples. The day 1 samples in this study
were taken anytime in the first 24 hours of an infant's life, hence could have been
influenced by postnatal treatments already. How true these associations ofNKA with
perinatal factors are is therefore unclear, and could be elucidated with cord blood
samples.
Plasma NKA could be perhaps be studied in an older group of verbal children over a
time when pain is being experienced, and in the recovery phase. This could comprise
children who are pre- and post-operative, and correlated with a verbal or pictorial
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pain scale. However, if these children receive adequate peri-operative analgesia, the
same problems could be encountered as in this study, where measurements were
probably taken in the absence of any pain sensation due to adequate therapy. An
alternative option would be to study children who have sustained a painful insult,
which is likely to be persistent, such as a bone fracture, and measure samples when
they are in pain and during the recovery period, again with a descriptive pain scale
for correlation.
These potential studies would be in older verbal children, to look for a relationship
between the neurochemical marker and the emotional sensation of pain. If found, the
results could be extrapolated to children of a similar age who may be non-verbal.
However, we would still have to be cautious in interpreting similar results in
newborn infants, as the neurobiology and neurophysiology is likely to be very
different.
Due to having an immature nervous system, newborn infants experience pain via
functional signalling pathways that are not found in mature individuals. Pain
signalling occurs via a complex interaction of neurotransmitters and neuromodulators
at different levels in the nervous system. As such, it is unlikely that any one
neurotransmitter can serve as a 'marker' for pain, and that perhaps a measure of
variations in a selected set of neurotransmitters may be more informative.
Furthermore, there is some evidence from animal studies that A fibres are also
involved in rapid nociceptive transmission in the newborn, especially premature, and
hence should also be investigated together with C fibre nociception4. However, as the
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study of the developmental neurobiology of pain signal processing advances, there is
hope that analgesic therapies which are more specific to newborn infants will be






Abbreviation Full name Manufacturer Serial no. Equipment
no.
Glass SPE tank 1ST VacMaster 1ST
Second SPE tank Vac-Elut Analytichem
International
Gamma counter Cobra II Auto-gamma Packard Canberra 403042 04787




White vortex mixer Autovortex Mixer
SA2
Stuart Scientific 6720 04792
Water bath W38 Grant 04796
Magnetic stirrer S/MAG/MINOR Voss Instruments
Ltd.
06203
Microfuge MBC Microfuge Hawksley
England
04721
pH meter pH Meter 240 Corning 04724
Pipettes Scalpettes (various) Jencons
Pipettes Proline (various) BioHit
Vacuum pump Aquavac Junior Aquavac
Uniscience
769 04793
Gyrovap Gyrovap Flowe & Co. UK GV1623 04681

























Sigma-Aldrich 25,235-2 77518 FW=372.24
Na azide Sodium azide 99% Sigma-Aldrich 19,993-1 40105
30610079
FW=65.01





Liquid Phase Extraction Procedure
Abbreviation Full name Manufacturer Product
no.
Lot no. Notes
Ace Acetone BDH AnalaR 100035R K27304306 58.08
PetEt Petroleum spirit
40-60°C




Solid Phase Extraction Procedure













Abbreviation Full name Manufacturer Product
no.
Lot no. Notes
MeOH Methanol BDH AnalaR 10158BG K26829270 32.04




























Abbreviation Full name Manufacturer Product
no.
Lot no. Notes
SP Antibody IDS/Eurodiagnostica A45 SP-2-840530
SP Tracer
SP Standard Peninsula 7451































































Trasylol Aprotinin Bayer CBVWU1
CBNPR1


















































Appendix B: Substance P liquid phase extraction procedure (Yanaihara)191
1. 1 ml cold acetone is slowly added to 0.5 ml sample while vortexing to obtain
a white precipitate. When not being handled, all tubes are kept capped to
minimise evaporative losses.
2. Samples are centrifiiged at 800G and 4°C for 10 minutes.
3. Supernatant is decanted and precipitate discarded.
4. 2 ml petroleum ether 40-60°C is added to supernatant.
5. Tubes are recapped and vortex mixed.
6. Samples are then centrifuged again at 800G and 4°C for 10 minutes.
7. Upper ether layer is discarded.
8. Lower acetone layer is dried under a stream of nitrogen at room temperature
and stored at -20°C until radioimmunoassay.




Appendix C: Solid phase extraction procedure: Mobile phase according to
Euro-Diagnostica22
1. Thaw the samples immediately before starting the extraction. Store at 2-8°C
until adding 1M HC1.
2. The column is wetted with 5 ml methanol.
3. Wash the column with 20 ml distilled water.
4. Apply 2 ml plasma sample to which has been added 0.2 ml 1M HC1 on the
column. The flowrate should not exceed 2 ml per minute.
5. Wash with 20 ml 4% acetic acid in distilled water.
6. Elute the peptide with 4 ml methanol and collect the eluate in a 10 ml conic
glass tube.
7. Evaporate the methanol in a stream of air or nitrogen.
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Appendix D
Appendix D: Solid phase extraction procedure: Mobile phase according to
Fehder224
1. Equilibrate columns with 5 ml methanol, followed by 5 ml distilled water.
2. Dilute sample 1:4 with 4% acetic acid (v/v) and vortex mix.
3. Load acidified sample onto column under gravity only.
4. Wash with 10 ml 4% acetic acid (v/v) under gentle vacuum.
5. Elute with 60% acetonitrile in 1% trifluoroacetic acid (v/v), prepared in
distilled water. Use 1 ml of eluant, under gravity only.
6. Dry eluate under a stream of nitrogen at 45°C in a water bath.
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Appendix E: Solid phase extraction procedure: Mobile phase according to
Peninsula (modified)22^
1. Acidify samples with equal volume of 1% TFA.
2. Centrifuge at 3900G and 4°C for 20 minutes.
3. Equilibrate 1ST Isolute CI8 SPE 50mg/lml columns with 1 ml 100% ACN
followed by 9 ml 1% TFA.
4. Load sample supernatant onto column under gravity only.
4. Wash with 6 ml 1% TFA under gravity.
5. Elute with 1 ml of 60% ACN in 1% TFA under gravity only and collect
eluant in a polypropylene tube.
6. Dry under a stream of nitrogen at 45°C in water bath.
TFA = trifluoroacetic acid
ACN = acetonitrile
SPE = solid phase extraction
1% TFA
Dilute 1 ml concentrated TFA slowly in 99 ml distilled wataer
60% ACN in 1% TFA
Dilute 0.4 ml concentrated TFA slowly in 39.6 ml distilled water




Substance P Radioimmunoassay Protocol
1. Set up SP standards in polypropylene tubes. Top standard is 500 pmol/L. Make
up with 50 pi working stock SP (50 nmol/L) into 4950 pi phosphate buffer.
Serially dilute 1:1 with more buffer to lowest standard 0.98 pmol/L.
2. Work out volume of SP antibody required (100 pi per assay tube). Dilute stock
antibody 1:400 with buffer to final concentration of 1:120000.
NB: Each 100 pi aliquot of SP stock antibody is sufficient for 400 mini assay
tubes
3. Label assay tubes as follows:
1-2 Totals
3-4 NSB











27-x Samples in duplicate
4. Pipette 50 pi buffer into NSB and Reference tubes. Pipette 50 pi standards into
respective assay tubes 7 - 26. Pipette 50 pi reconstituted sample extracts in
duplicate into relevant tubes. Totals contain only tracer.
5. Using repeater, pipette 100 pi SP antibody into each assay tube except Totals and
NSB. Vortex mix all tubes and incubate at 4°C for 24 hours.
6. Work out volume of SP tracer required (100 pi per assay tube). Dilute stock
tracer 1:40 with buffer.
7. Pipette 100 pi SP tracer into each assay tube. Vortex mix all tubes and incubate
at 4°C for 24 hours.
8. Mix Sac-Cel well for 5 minutes. Using repeater, pipette 50 pi Sac-Cel into each
assay tube except Totals. Vortex mix all tubes and incubate at 4°C for 1 hour.
9. Centrifuge at 1700G and 4°C for 15 minutes (Program 15).
10. Decant supernatants and count pellets in gamma counter on Program 54.
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Neurokinin A Radioimmunoassay Protocol
1. Set up NKA standards in polypropylene tubes. Top standard is 1000 pmol/L.
Make up with 50 pi working stock NKA (1 nmol/L) into 4950 pi phosphate
buffer. Serially dilute 1:1 with more buffer to lowest standard 1.95 pmol/L.
2. Work out volume ofNKA antibody required (50 pi per assay tube). Dilute stock
antibody 1:75 with buffer.
NB: Each 100 pi aliquot of NKA stock antibody is sufficient for 150 assay tubes
3. Label assay tubes as follows:
1-2 Totals
3-4 NSB
5-6 Reference (0 pmol/L)
7-8 1.95 pmol/L
9- 10 3.9 pmol/L
11-12 7.8 pmol/L
13-14 15.6 pmol/L
15- 16 31.2 pmol/L
17- 18 62.5 pmol/L
19-20 125 pmol/L
21 -22 250 pmol/L
23-24 500 pmol/L
25-26 1000 pmol/L
27-x Samples in duplicate
4. Pipette 50 pi buffer into NSB and Reference tubes. Pipette 50 pi standards into
respective assay tubes 7 - 26. Pipette 50 pi reconstituted sample extracts in
duplicate into relevant tubes. Totals contain only tracer.
5. Using repeater, pipette 50 pi NKA antibody into each assay tube except Totals
and NSB. Vortex mix all tubes and incubate at 4°C for 24 hours.
6. Work out volume ofNKA tracer required (50 pi per assay tube). Dilute stock
tracer 1:60 with buffer.
7. Pipette 50 pi NKA tracer into each assay tube. Vortex mix all tubes and incubate
at 4°C for 24 hours.
8. Mix Sac-Cel well for 5 minutes. Using repeater, pipette 50 pi Sac-Cel into each
assay tube except Totals. Vortex mix all tubes and incubate at 4°C for 1 hour.
9. Centrifuge at 1700G and 4°C for 15 minutes (Program 15).





THERE ARE SPECIAL SALIVA AND BLOOD TUBES FOR THIS STUDY.
1. Check on babies and nursing staff quickly
a) Must be >Vi hour since any feeds
b) Note general condition and write down times of last handling and last
feed. Fill in a Sample Collection Details form
2. Perform saliva suction at -15 mmHg with trap (maximum 10 minutes
duration).
3. Cap saliva trap immediately and place in -20°C freezer. Note time ofend of
suction.
4. Perform venepuncture, collecting 0.75 - 1 ml into white microtube. Keep on
ice when not being handled. Note time ofsampling.
5. Spin white microtube in microfuge for 1 minute. Remember to use the
appropriate green balance.
6. Aliquot plasma - only 3 drops into yellow microtube
- rest of plasma into pink microtube
7. Mix pink tube well so preservative dissolves and place in -20°C freezer.






An investigation into the measurement of pain and stress in newborn infants
Babies cannot easily tell us when they are comfortable or when they are in pain.
Because we look after a lot of ill babies we would like to learn reliable ways of
deciding how comfortable they are. We are performing a study in the neonatal unit
to try and find out more about this, to help us improve the way that we can look after
babies in the future.
We know that when adults are in pain their bodies produce chemicals called
substance-P, neurokinin-A and Cortisol that circulate in their blood, but we do not
know if this occurs in newborn babies. These chemicals can be measured using a
small blood sample. We are trying to find out if the same measurements can be
useful in newborn babies and if these chemicals are also present in the saliva as
well as the blood. To do this we would like to ask your permission to collect a small
sample of blood (0.5ml) and a small sample of saliva (0.25ml) from your baby. The
blood sample would be collected at a time when your baby's doctor was doing a
blood test anyway so there would not be any extra needle-punctures required for the
study. The saliva would be collected by gently sucking it into a small tube placed in
your baby's mouth. Neither the blood sample nor the saliva sample would be
stressful or harmful to your baby.
If you allow your baby to be included in this study it may help us understand more
about how to assess pain in newborn babies, but the study will be of no direct
benefit to your child. The study does not involve any treatments and your baby will
be cared for in exactly the same way whether or not you choose to give us your
permission. If you give us your permission, you will be free to change your mind at
any time. If you would like any more information about this study please feel free to
ask at any time.
For further information, please ask for:
Dr Mae Wong




LOTHIAN RESEARCH ETHICS COMMITTEE
STANDARD CONSENT FORM
TITLE OF THE PROPOSED RESEARCH:
An investigation into the measurement of pain and stress in newborn infants
NAME OF INVESTIGATORS:
Dr Mae Wong, Dr Ben Stenson, Dr Ian Laing, Dr Andy Lyon, Professor Neil
Mcintosh
ADDRESS:
Neonatal Unit, Simpson Memorial Maternity Pavilion, Edinburgh
TELEPHONE:
0131-5364350
FURTHER INFORMATION IS AVAILABLE FROM: (A person who is not involved in
the study) Dr Paula Midgley
□ I agree to my child participating in this study.
□ I have read this consent form and Parent Information Sheet and had the opportunity to ask
questions about them.
□ I agree for notice to be sent to my child's General Practitioner about their participation in
this study.
I agree to the provision of any clinically significant information to my child's General
Practitioner.
I understand that my child is under no obligation to take part in this study and that a
decision not to participate will not alter the treatment that my child would normally receive.
I understand that my child has the right to withdraw from this study at any stage and that to
do so will not affect their treatment.
I understand that this is non-therapeutic research from which my child cannot expect to
derive any benefit.
Name of Patient:
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THE EFFECT OF PAIN ON PLASMA SUBSTANCE P & NEUROKININ A IN
NEONATES
C Mac Wong, Elaine M Boyle, Ian A Laing, Rhona I Stephen, John Smith, Neil Mcintosh
Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh City: Edinburgh, UK
Background: Substance P (SP) and neurokinin A (NKA) are neuropeptides involved in pain
sensory signal processing1. They can be measured in plasma and have been associated with pain and
inflammation in adults . There is a possible role for them as markers of persistent pain in neonates,
but this has not previously been investigated. The aim was to determine whether plasma SP and NKA
levels varied with pain. Methods: This was a prospective case-controlled observational study. Rom
July 2000 to December 2001, blood samples were collected longitudinally from 19 neonates believed
to be suffering pain, e.g. due to surgery, necrotising enterocolitis, severe intraventricular haemor¬
rhage, and meningitis. 19 controls matched for gestation and ventilatory status were recruited.
Gestation ranged from 25—41 weeks. Only one sample per infant per day was taken between 0800
and 1200 hours. Neuropeptides were extracted, then measured using an in-house radioimmunoassay.
Results were analysed using the Mann-Whitney U test. Results: Area under the curve (AUC) was
calculated for three consecutive daily neuropeptide levels. There was no significant difference in
median AUC for either SP (pain=3.79, control=3.03, P=0.8) or NKA (pain=10.2, control= 123,
P=0.3). One limitation of this observational study was that 15 of 19 infants believed to be suffering
pain already received analgesia prior to study enrollment Analysis of the 4 who had not received
prior analgesia yielded no significant differences compared with either those who had received
analgesia, or the controls. Graphs of peptide levels over time were also examined for individual
infants and no consistent change noted with pain or analgesia administration. Conclusion: This is the
first study of SP and NKA levels in neonates. Pain does not appear to have a significant effect on
levels of either neuropeptide. This may be due to adequate treatment of pain with analgesia
administration. It is also possible that some or all of the infants were not in pain. Only 4 did not
receive analgesia. The appropriate treatment of pain should not be withheld for any study. Therefore,
it may be more feasible to study SP and NKA levels in a population of infants who are not routinely
receiving analgesia, but exposed to another source erf possible pain or distress, such as assisted
ventilation. 1. Fleetwood-Walker S. Current Opinion in Anaesthesiology 2:645-648, 1989. 2.
Marshall KW. Arthritis and Rheumatism 33(l):87-90,1990.3. Gallai V. Cephalalgia 15(5):384-390,
1995.
IN-LINE PRESSURE MEASUREMENTS IN A MODEL OF 3-COMPONENT
LV. THERAPY.
'R Gelissen, ]R van Rens,2M Schasfoort 2H vd Waterbeemd, 3R Berendsen, "P Andriessen
Maxima Medical Center, 'NICU, 2Medical Technology, 3Depart of Clinical Physics, City: Veld-
hoven. The Netherlands (sponsor CE Blanco)
Aim: We investigated (in-line) pressure course during and after occlusion of different pumps in a
simulation model in order to choose an appropriate pump system for our (pre)term infants. Methods:
5 different (syringe) pumps were tested in the study. The model simulated i.v. therapy of 3
components, comparable to T.P.N. administration used in a 1-kg preterm infant The pumps were
positioned vertically: Upper pump (UP) with a flow rate of 23 ml/h, middle pump (MP) with a flow
rate of 1,6 ml/h and the lower pump (LP) with a flow rate of 03 ml/h. In-line pressure was measured
using a DTX™ Plus Transducer (sampling rate of 1 Hz) at UP, MP, LP and just before the location
of the IV administration. Measurements per model in triplicate: Atl time delay between start of
infusion therapy and first droplet was used as an estimate of "being on pressure" of the system, At2
time delay between occlusion and first alarm, At3 time delay between discontinuing the occluding
pump and second alarm, AP automatic pressure decline after attaining the pressure limit was used as
an estimate for in-line mixing of components. Data expressed as mean (SD).
Results:










Conclusion: Considerable differences exist in (in-line) pressure course and alarm function be¬
tween the pumps. 4 out of 5 are on pressure within 1 min. Braun and Alaris react quicker after
occlusion. In-line mixing between the different components was remarkably less with Braun and
Alaris.
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SUBSTANCE P & NEUROKININ A IN NEONATES: EFFECT OF VENTILA¬
TION & ANALGESIA
C Mae Wong, Elaine M Boyle, Ian A Laing, Rhona I Stephen, John Smith, Neil Mcintosh
Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh City: Edinburgh, UK
Background: Substance P (SP) and neurokinin A (NKA) are neuropeptides involved in trans¬
mission and modulation of pain signals'. They are measurable in various body fluids and have been
associated with pain and inflammation in adults. They could potentially be neurochemical markers of
pain in neonates. The aims of this study were to investigate the effect of ventilation on SP and NKA
levels in preterm infants, and to see if analgesia affected these levels. Methods: From July 2000 to
December 2001, blood samples were collected longitudinally from 142 neonates, gestation 23-42
weeks. Only one sample per infant per day was taken between 0800 and 1200 hours. Plasma was
extracted and neuropeptides measured using an in-house radioimmunoassay. Infants with presumed
painful conditions were excluded. Results were analysed using the Mann-Whitney U test Results:
Median neuropeptide values (pmol/L) are tabulated. Table la shows SP results from all neonates
grouped by ventilation, and Table lb shows corresponding NKA results. SP levels were not found to
be significantly higher in ventilated infants. NKA levels were significantly lower in ventilated infants
on days 1 & 2, and higher on days 7 & 14. Of 142 neonates, 33 infants ^32 weeks' gestation were
also enrolled into a randomised double-blinded controlled trial investigating the routine use of
morphine infusions to sedate ventilated preterm infants. All infants on a study drug infusion (21
morphine, 12 placebo) were ventilated. Gestation, birth weight and antenatal factors were similar in
both groups. Area under the curve (AUC) was calculated for neuropeptide levels on days 1 to 3. There
was no significant difference in median AUC for SP (morphine=331, placebo=338, P=03).
Median AUC for NKA was significantly lower in those ventilated infants who received morphine
(morphine= 11.4, placebo= 13.0, P=0.05). Conclusion: This is the first study to investigate changes
in SP and NKA levels with ventilation. SP levels do not appear to be a useful marker of persistent
pain or distress. Conversely, NKA levels show significant changes with ventilation, and are further
modulated by the use of analgesia. We previously reported Cortisol responses in the same group of
infants, demonstrating significant changes with ventilation but not with analgesia2. It appears that
although Cortisol is a useful indicator of overall stress, NKA might be more specific for pain.
LEVELS OF IGF-IVEGF IN RHUEPO TREATED PREMATURES FOR ANE¬
MIA OF PREMATURITY (AOP): ASSOCIATION WITH RETINOPATHY OF
PREMATURITY (ROP), (PILOT STUDY).
Soubasi V. Diamanti E, Vyzantiadis T, Spandou E, Laporda A, Tsantali Ch, Kremenopoulos G.
Depts of Neonatology, Physiology, Lab of the 2nd Prop Dept of Internal MedicineAristotle Univer¬
sity of Thessaloniki. City: Thessaloniki, Greece
Background: Based on experimental data on adult murine retinas, systemic application of rHuEpo
crosses the blood-retina barrier. Also, when it was administered before or immediately after retinal
ischemia, not only reduced histopathological damage but promoted functional recovery (Grimm et al
Nat Med 2002). Besides, VEGF is instrumental in the development of abnormal retinal vasculature
and IGF -1 is necessary at minimal levels to promote maximum function of VEGF. When IGF-I is
persistently low, vessels cease to grow and VEGF accumulates in the vitreous, leading subsequently
in neovascularization and ROP. Erythropoietin (Epo) interacts with VEGF to potentiate its vascular
activity. Epo and VEGF often co-distribute and are regulated by hypoxia inducible factor (HLF-
I).OBJECTIVE: The aim of this prospective controlled study was to assess, if early rHuEPO
treatment for AOP would have a preventive effect in ROP through optimizing both VEGF and IGF-I.
Methods: 15 premature neonates (GA<30 wks, BW<1250g) were entered in a randomized con¬
trolled study of rHuEPO treatment The neonates assigned to receive either rHuEPO (250 units/g/
every other day) or not early after birth. Levels of VEGF and IGF-I were measured in both serum
and plasma at 1st ,12-16th and 30-35th day after birth using enzyme immunoassay and immunora-
diometric assay respectively. Clinical and ROP data were recorded. VEGF and IGF-I levels were also




□ con ■ Epo □ fullterm
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□ con ■ Epo □ fullterm
30 day
1. Fleetwood-Walker S. Current Opinion in Anaesthesiology 2:645-648, 1989. 2. Wong CM.
Pediatric Research 52(5):787, 2002.
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in the duration of insult which is required to produce an isoelectric EEG [2], and human
babies are not subjected to identical and reproducible insults. Despite this, we felt that it
would be interesting to examine the relationship between the EEG determination ofseizure
onset time and our best estimate of the time ofany fetal/neonatal insult in the human body.
Aims: To establish whether or not the time of seizure onset, as determined by EEG
monitoring, was related to the time of the fetal/neonatal cerebral insult [3]. Previous work
has examined the time ofclinical seizure onset, which is unreliable when compared to EEG.
Methods: Babies who were considered to be high risk of seizure were monitored
prospectively using 12-channel continuous video-EEG telemetry, with parental consent.
The best estimate of the time of brain injury was determined by careful review of the CTG
traces, the obstetric history, and the peripartum events by an observer (AD) who was blind
to the EEG findings. In one case, there were neuropathological findings from autopsy.
Results: Eight babies with hypoxic-ischaemic encephalopathy had monitoring com¬
menced sufficiently early to allow detection of the time of first electrographic seizure, and
a further baby was already seizing when monitoring began (at 5 h). In three babies, it was
thought that the insult had occurred before labour and more than 12 h before birth. In this
group, the EEG seizure onset time was 4, 5.5, and 9.5 h, respectively. These babies began
seizing earlier than the six whose insult was thought to have occurred during labour or
close to the time ofbirth. In these babies, the first seizure was detected at 11.5, 12, 13, 18,
20, and 26 h after birth. This gave a median seizure onset time of 15.5 h compared to 5.5
h (Mann—Whitney p-value = 0.02).
Conclusion: Babies who had suffered an acute hypoxic—ischaemic insult close to birth had
their first EEG seizure later than those whose history suggested that their brain injury was
sustained before labour began. The EEG in this group followed a very similar pattern to that
seen in the lamb model after an acute insult. Our results suggest that babies with EEG
seizure onset at less than 6 h probably did not sustain their brain injury at around the time of
birth. Continuous EEG monitoring from birth may allow amore precise estimate ofthe time
of brain injury to be made than that which is currently possible with other methods.
References
[1] Williams CE, Gunn AJ, Mallard C, Gluckman PD. Outcome after ischemia in the developing sheep brain: an
electrographic and histological study. Ann Neurol 1992;31:14-21.
[2] Mann LI, Prichard JW, Symmes D. EEG, ECG, and acid-base observations during acute fetal hypoxia. Am J
Obstet Gynecol 1970;106:39-51.
[3] Hollier LM. Can neurologic injury be timed? Semin Perinatol 2000;24:204-14.
Plasma substance P and neurokinin A in neonates—variation with gestation and
postnatal age
C. Mae Wong, Elaine M. Boyle, Ian A. Laing, Rhona I. Stephen, John Smith,
Neil Mcintosh
72 Abstracts
Neonatal Unit, Simpson Centre for Reproductive Health, Royal Infirmary of Edin¬
burgh, Edinburgh EH16 4SA, UK
Background: Substance P (SP) and neurokinin A (NKA) are neuropeptides involved in
transmission and modulation of pain signals [1], They are measurable in plasma and
have been associated with pain in adults [2,3]. There is a potential role for them as
neurochemical markers of pain in neonates, but this has been previously investigated.
Aim: As a baseline to studying plasma SP and NKA as possible markers of pain in
neonates, the effect of gestation and postnatal age was studied to establish 'normal'
values.
Methods: From July 2000 to December 2001, longitudinal once-daily morning blood
samples were collected on days 1, 2, 3, 7, and 14 neonates, gestation 23-40 weeks.
Peptides were extracted, then quantified using an in-house radioimmunoassay. Infants with
presumed painful conditions were excluded.
Results: Overall, SP levels ranged from 0.0 to 11.2 pmol/1 (median 1.7 pmol/1) and NKA
levels from 1.8 to 74.6 pmol/1 (median 6.0 pmol/1). Gestation and birth weight had no
significant correlation with peptide levels. Postnatally, there was a gradual rise in median
SP during the first 3 days which decreased again by day 14 (median NKA showed a
similar rise over the first 3 days but decreased by day 7). These patterns were more
apparent in preterm infants < 32 weeks' gestation.
Conclusions: This is the first description ofnormative values of SP and NKA in neonates.
SP and NKA show changes with postnatal age, more marked in preterm infants. In early
postnatal days, multiple factors may influence SP and NKA levels, including antenatal
circumstances, ventilation, parental nutrition, and drugs. Further elucidation of these
factors is warranted.
References
[1] Fleetwood-Walker S. Curr Opin Anaesthesiol 1889;2:645-8.
[2] Marshall KW. Arthrit Rheum 1990;33(l):87-90.
[3] Gallai V. Cephalalgia 1995;15(5):384-90.
The predictive value of EEG monitoring for subsequent intracerebral complications
during ventilation in preterm infants
Henning Wulbrand
The Eppendorf Center for Pediatric Neurology, Hamburg, Germany
Objectives: Only little data exist on bioelectrical activity of the brain in preterm infants
during the periods of increased risk of intracerebral impairment during the first days of
life.
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Purpose of the study: To evaluate the quality of care delivered by Advanced Neonatal
Nurse Practitioners at Ashington Hospital.
Methods: A novel methodology for confidential enquiry was developed, which allowed
aspects of high-quality practice to be captured as well as suboptimal care. Sentinel cases
included all babies who, within the first postnatal week, either died, transferred out, or
developed convulsions. Five other hospitals, all with different models of neonatal care,
but all based on hierarchies of medical staff, were chosen as comparators. Eight
dimensions of care were each rated on a scale of 0 to 4 (from seriously deficient to
exemplary). Case notes for babies bom between April 1998 and March 1999 were
anonymised and assessed blind by four raters. If predefined standards of concordance
were not met, the notes were rated by a panel independent of any of the participating
hospitals, and this rating was taken as definitive. Arithmetical means of the scores were
taken for each relevant dimension of care for each case, and the mean for each case was
averaged for each hospital.
Results: Eighty-two cases were analysed. The dimension relating to terminal care had
insufficient numbers for inclusion. The lowest score for any single case was 0.49 and the
highest was 3.07; neither case was from Ashington. Mean scores for the comparator
hospitals were 1.80, 2.13, 2.32, 2.23 and 2.43. The mean for Ashington was 2.35.
Results for each dimension for Ashington are related to the means for all the comparator









Transfer out 2.07 2.21
Conclusions: The quality of care of these sentinel cases appeared to be at least as good
when provided by Advanced Neonatal Nurse Practitioners alone as when delivered by
medical models of neonatal care. These data support the contention that good quality
neonatal care can be delivered by Advanced Neonatal Nurse Practitioners alone and does
not require the presence of resident junior paediatricians.
Changes in plasma Cortisol with ventilation and analgesia in preterm infants
C Mae Wong, Elaine M Boyle, Ian A Laing, Joan Yorke, Jaqi Armstrong, John Smith,
Paula C Midgley, Neil Mcintosh
108 Abstracts
Neonatal Unit, Simpson Centre for Reproductive Health, Royal Infirmary of Edin¬
burgh, Edinburgh EH16 4SA, UK
Background: Plasma Cortisol can be used as a marker of pain and stress in neonates1.
Preterm infants often require assisted ventilation, but analgesia is not used routinely.
Aims: To investigate the effect of ventilation on plasma Cortisol levels in preterm infants,
and to see if analgesia affects these levels.
Methods: From July 2000 to December 2001, longitudinal once-daily morning blood
samples were collected from 88 neonates < 32 weeks gestation. Plasma Cortisol was
measured by a direct in-house radioimmunoassay. Infants with painful conditions were
excluded. No infant received postnatal steroids. Results were analysed by Mann-Whitney
U-test.
Results: Median Cortisol values (nmol/1) are tabulated. Table 1 shows results from the 88
neonates grouped by ventilation. All the ventilated babies are shown in Table 2 grouped
by analgesia. Within this ventilated cohort was a subgroup of infants randomised in the
NEOPAIN Trial to morphine or placebo infusions. Samples taken during assisted
ventilation showed significantly higher Cortisol levels. However, there was no significant
difference in Cortisol levels between the groups receiving analgesia or no analgesia.
Similar results were obtained with samples from the subgroup of NEOPAIN infants.
There was no difference in gestation or birth weight between those who received
analgesia and those who did not.
Table 1
Postnatal day Ventilated Not Ventilated P value
N Cortisol N Cortisol
1 34 309.7 18 99.5 0.006
2 35 310.0 17 107.8 0.001
3 36 209.1 39 133.3 0.002
7 26 273.1 45 176.9 0.009
14 19 211.6 38 147.7 0.05
Table 2
Postnatal day Morphine No morphine P value
N Cortisol N Cortisol
1 19 351.1 15 199.1 0.19
2 17 292.4 18 356.1 0.30
3 17 207.3 19 286.8 0.68
7 6 350.1 20 273.1 0.93
14 4 207.6 15 211.7 1.00
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Conclusions: Assisted ventilation is associated with raised plasma Cortisol levels in
preterm infants. This could be due to the underlying cause ofthe need for ventilation or the
pain or stress of ventilation itself. However, analgesia has no effect on these levels in
ventilated infants, suggesting either that morphine is ineffective in ameliorating pain or
that the stress of ventilation is not related to pain.
Reference
[1] Anand KJ. NEJM 1992;326(l):l-9.
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EFFECTS OF OXYGEN TENSION (OT), CORTICOSTERONE (CST) AND CORTICO-
TROPIN-RELEASING-HORMONE (CRH) ON NA+ TRANSPORT IN RAT FETAL AL¬
VEOLAR CELLS
Ulrich H- Thome, Ian C. Davis, Susie V. Nguyen, Janice Ware, Brent J. Shelton, and Sadis Matalon,
University of Alabama at Birmingham, Birmingham AL, USA
Background: Oxygen and steroids are involved in mediating the transition from fluid secretion to fluid
absorption in the perinatal lung. CRH is thought to control the timing of birth in several species.
Aims: To investigate how OT, CST and CRH affect active Na+ transport by fetal distal lung epithelia
(FDLE) isolated from 19 d rat fetuses (term: 22d).
Methods: FDLE were grown to confluent monolayers on permeable supports in 5, 12 or 20% 02 with 5%
C02, using serum free media supplemented with 1 /unol/1 CST and/or 3 nM CRH. Short circuit currents
(ISC) were measured in Ussing chambers. Baseline ISC (BS), generated by intact cells, ouabain sensitive ISC
(OS) and amiloride sensitive ISC (AS) were measured. Expres-sion of Na+ transport proteins was deter¬
mined by SDS-PAGE and Western blot.
Results: Data from 250 monolayers, 4-11 per condition, were analyzed with 3-way ANOVA. With increasing
OT during culture, baseline ISC (BS) increased from 5J±0.2 /tA/cm2 at 5%, to 8.4±0.3 pAJcml at 20%
(p<0.001). OS increased from 3.4±0.6 to 9.1 ±0.6 /iA/cm2 (p<0.001), and AS from 3.4±0.2 to 43±0.2
jiA/cm2 (p<0.01). CST did not change BS or OS, but increased AS from 3.1 ±0.2 to 4.6±0.2 pA/cm2
(p<0.001). CRH did not have an effect on ISC. Protein expression was analyzed in cells derived from 4
different isolations. Culture under 5% 02 in the presence of CST significantly reduced expression of a-, b-,
and g-ENaC and al-NaJC-ATPase subunits, but did not change the bl-Na,K-ATPase subuniL Expression of
these proteins was similar in cultures grown under 20% 02 with or without CST, or 5% 02 without CST.
Conclusion: Increased OT exposure resulted in increased basolateral Na,K-ATPase function as well as apical
Na+ permeability, whereas CST only increased apical Na+ permeability, thus limiting the effect of CST on
maximum Na+ transport. CRH did not affect Na+ transport Changes in function did not correlate well with
changes in transport protein expression.
INCIDENCE AND RISK FACTORS FOR HEARING LOSS IN DUTCH NICU-INFANTS
ETM Hille1, HLM van Straaten2, PH Verkerk1.1 TNO-PG. Leiden, 2 Isala Clinics, Zwolle. The Netherlands
Aim: To determine the incidence and risk factors for congenital hearing loss (CHL) in at risk newborns in the
Netherlands. Design: Automated Auditory Brainstem Response (AABR) hearing screening has been intro¬
duced since 1998 in the Dutch Neonatal Intensive Care Units (N1CU). The results of all NICU-graduatcs are
registered in a central database to facilitate the services needed for screening and following up of all infants
with abnormal screening results. All NICU-graduates with one of more risk factors according to the Joint
Committee on Infant Hearing were included in a two stage program. After a second failure diagnostic ABR
was used to establish diagnosis of CHL Newborns who died before the age of 3 months were excluded.
Statistics: Univariate analyses of risk factors for CHL were performed. Results: In December 2001 4562
newborns (born before 1st of April 2001), median age 32 weeks (24-43) and 1455g (500-4850), have been
included. The overall incidence of uni- or bilateral CHL after diagnostic ABR was 132/4562 (2.9%). Table:
Odds Ratios (OR; 95%CI) of risk factors for CHL
Conclusion: AABR hearing screening in
Dutch NICU-infants revealed an overall in¬
cidence of 2.9% CHL Univariate analysis
revealed that the following NICU-infants
Both weight <1500# 0.6 [0.4-0.8) are at increased risk: infants with CHL in
the family, craniofacial anomalies, a birth
Table: Odds Ratios (OR; 9S%CI) of risk factors for CHL
on ostcrt
Familial CHL 3.5 fl .6-7.81
7.1 [43-1231
. [0.4-0.81
Hyperbilirubinemia requiring exchange 1.4 [0.6-3.4]
Ototoxic medications 13 [0.8-2.41
Cerebral complications 2.1 [1.4-33] weight sL500g, cerebral complications.
Low APGAR score 1.2 [0.8-1.7] mechanical ventilation 3r5 days, and syn-
Mechanical -rentilarioj >5 days 1.6 [1-2-2-4] dromes associated wilh CHL.Syndromes associated with CHL 5.5 [3.2-9.21
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REACTIVE INTERMEDIATES OF SIN-1 MODULATE CHLORIDE SECRETION
ACROSS MURINE AIRWAY CELLS
Ulrich H. Thome, Ahmed Lazrak, Lan Chen. Michael J. Thomas (1), Henry Jay Forraan and Sadis Matalon,
University of Alabama at Birmingham and (1) Wake Forest University, Birmingham AL USA and (1)
Winston-Salem NC. USA
Background: Reactive oxygen/nitrogen species are generated in increased amounts during inflammatory
processes and may affect epithelial ion transport.
Aims: To quantify the effects of reactive oxygen-nitrogen intermediates on chloride (CL) currents across
cultured murine tracheal epithelia] (MTE) cells.
Methods: Reactive species were generated by decomposition of 3-morpholinosydno-ninline (SIN-1). Water¬
tight MTE monolayers were grown on permeable supports. The effects of SIN-1 on short-circuit currents
(ISC) were measured in Ussing chambers after completely blocking Na+ currents with amiloride (10/xM).
Single MTE cells were grown on glass coverslips, and the effects of SIN-1 on whole cell current and single
CI- channels were studied by the patch clamp method in whole-cell and cell-attached mode, using Na+-free
solutions. Spectrophotometry and clectrospray mass spectroscopy were used to identify new compounds.
Results: ISC increased after addition of SIN-1 (I mM) from 7.6 ± 031 /xA/cm2 to 35 ± 13 /iA/cm2 (X ±
- 1 5E) within 3G-6G nun \;ECL50 = 7 fiMj, ana returned to baseline values by 120 mm. Forskolin (10 mM)
augmented the SIN-1 effect when added early on, but failed to increase ISC when added 40-80 min post
SIN-1. The ISC increase was blocked by glibenclamide (200 /iM) or 5 mM reduced glutathione. In patch
clamp experiments, SIN 7 temporarily increased whole cell CI- current 4-fold, and open probability of single
cystic fibrosis transmembrane regulator channels from 0.041% to 0.92%. Decomposed SIN-1 also increased
ISC with an EC50 of 5 /iM. Spectrophotometry and electrospray mass spectroscopy revealed the formation
of several new compounds during the decomposition of SIN-1.
Conclusion: One or more of the metastable compounds formed during SIN-1 decomposition caused a
transient increase, followed by a decrease, of epithelial CI- transport.
INFLUENCE OF VENTILATION & ANALGESIA ON PLASMA CORTISOL IN PRE¬
TERM INFANTS
C Mae Wong, Elaine M Boyle,. Ian A Laing, Joan Yorke, Jaqi Armstrong, John Smith. Paula Midgley. Neil
Mcintosh, Simpson Centre for Reproductive Health, Edinburgh
Background: Plasma Cortisol can be used as a marker for pain and stress in neonates. Preterm infants often
require assisted ventilation but analgesia is not used routinely. The aims of this study were to investigate the
effect of ventilation on plasma Cortisol levels in preterm infants, and to see if analgesia affected these levels.
Methods: From July 2000 to December 2001, samples were collected longitudinally from 88 neonates jU32
weeks gestation. Only one sample per infant per day was taken between 0800 and 1200 hours. Plasma Cortisol
was measured by a direct in-house radioimmunoassay. Infants were excluded from analysis if they had a
known painful condition at the time of sampling. No infant received postnatal steroids. 33 of the 88 infants
were also enrolled into a randomised double-blinded controlled trial (RCT) investigating the routine use of
mor,:hine infusions to sedate ventilated preterm infants. AQ infants on a study drug infusion (21 morphii c.
12 placebo) were ventilated. Gestation, birth weight and antenatal factors were similar in both groups. Results
were analysed using the Mann-Whitney U test Results: Median Cortisol values (nmol/L) are tabulated. Table
la shows results from the 88 neonates grouped by ventilation. Table lb shows results from the subgroup of
33 RCT infants on a study drug infusion.
Table la
Pcstnatal Ventilated Not Ventilated
day N Cortisol N Cortisol
1 34 309.7 18 993
2 35 310.0 17 107.8
3 36 209.1 39 1333
7 26 273.1 45 176.9
























Samples taken during assisted ventilation showed significantly higher Cortisol levels. However, there was no
significant difference between Cortisol levels taken while on morphine versus placebo infusions. Conclusions:
Ventilation is associated with raised plasma Cortisol levels in preterm infants. This could be due to the
underlying cause of the need for ventilation, or the pain or stress of ventilation itself. However, analgesia has
no effect on these levels in ventilated infants. This suggests either that morphine is ineffective in ameliorating
pain, or that the stress of ventilation is not related to pain.
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FATTY ACID STATUS IN BREASTFED AND FORMULA FED HYPERPHENYLALA-
NINEMIC (HPA) INFANTS AT DIAGNOSIS.
C Agostoni, E Riva, E Verduci, F Salvini, L Rori, A Zenga, M Giovannini. Dept. of Pediatrics, San Paolo
Hospital, Milan
Objectives. To compare biochemical parameters potentially associated with the later neurodevelopmental
outcome (blood Phenylalanine, Phe, and fatty acids) between breastfed (BF) and formula-fed (FF) infants
with HPA Study design. In a cross-sectional study all HPA detected by newborn screening and referring to
our Center in the last 2 years have been sampled for plasma Phe and fatty acids at entry and compared
according to the early type of feeding. Methods. Blood Phe by amino arid analyser, FA by capillary
gas-chromatography, statistics with Mann-Whitney non-parametric test Results. Twenty-six subjects (17,
BF, and 9, FF) were admitted. Themedian age for both groups at blood sampling was 18 days (ranges: 15-20
d for BF, 15-22 for FF). Plasma values (mean+SD) are reported in the Table.
Parameter BF (n=17) FF (n=9) P
Phe (umoI/L) 1177+987 1153+1104 0.98
C18:2n-6 % 20.8+ 3.0 24.7+4.4 0.01
C20:4n-6 % 83 + 23 5.4+13 0.001
CI83n-3% 0.25+0.11 031+032 0.003
C203n-3 % 031+036 0.18+0.07 0.10
C22:6n-3 % 2.t + 0.7 13 + 03 0.06
Conclusions. Differences in the early LCPUFA more than Phe status could be involved in the differences
found in the later outcome described in BF vs FF children with HPA, but a cause-effect relationship should be
investigated in long-term follow-up studies.
Conclusions. Differences in the early LCPUFA more than Phe status could be involved in the differences
found in the later outcome described in BF vs FF children with HPA, but a cause-cffect relationship should
be investigated in long-term follow-up studies.
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DIGOXIN-LIKE IMMUNOREACTIVE SUBSTANCE IN NONOLIGURIC HYPERKALE¬
MIA
Eva Mildenberger. Kathrin Oels, Karl Bauer, Martin Paul. Hans T. Versmold, Dept. of Pediatrics, Univer-
sitatsklinikum Benjamin Franklin, Berlin, Germany
Background / Aims: At around 24 h after birth very premature infants often present with an yet unexplained
shift of potassium from the intra- into the extracellular space. This nonoliguric hyperkalemia probably results
from a transient inhibition of the membrane-bound Na-+/K+-ATPase. The serum of premature infants has
endogenous digitalis-like activity, which inhibits the Na+/K+-ATPase as do digitalis glycosides. We
hypothesized that this endogenous digitalis-like activity triggers hyperkalemia.
Methods: Serum concentrations of potassium ([K-F]) and of the digoxin-ltke immunorcactive substance
([DLIS]) were measured during the first 24 h after birth in 60 infants including 30 infants < 30 gestational
weeks (wks).
Results: [K+] at 24 h after birth was related to gestational age (r2 = 0.48) and mean [K+] at 24 h after birth
was higher in infants below 30 wks than in infants > 30 wks (5.7 +/- 1.0 (SD) (3.9 - 7.9) mmol/I vs. 4.3
+/- 0.6 (33 - 53) mmol/1. p < 0.0001). There was a negative linear correlation between [DLIS] at birth and
[K+] at 24 h after birth (r2 = 0.24). Contrary to our hypothesis, infants with lower [DLISJ at birth had higher
[K+] at 24 h after birth. At 24 h after birth there was no correlation between [DLIS] and [K+]. At this time
mean [DLIS] was similar in infants below and above 30 wks (0.5 +/- 0.3 (0 - 1.0) ng/ml vs. 0.6 +/- 0.2 (0.2
- 1.1) ng/ml, p = 0.07).
Conclusion: We doubt a major role of DLIS in nonoliguric hyperkalemia of the premamrc infant.
